C. Vitae Jordi Monés 1
CURRICULUM VITAE,
Sept, 2017
Jordi M. Monés
PERSONAL DATA.
1. EDUCATION / QUALIFICATIONS
2. PRESENT PROFESSIONAL POSITIONS
3. PAST POSITIONS
4. INTERNATIONAL AWARDS
5. ADVISORY BOARDS and RESEARCH COMMITTEES
6. COLLABORATIVE EUROPEAN RESEARCH PROJECTS
7. BASIC RESEARCH PROJECTS
8. CLINICAL TRIALS
9. SCIENTIFIC PUBLICATIONS
10. SCIENTIFIC PRESENTATIONS
11. GRANTS
12. TEACHING ACTIVITIES and INVITED LECTURES
13. COLLABORATION IN JOURNALS EDITION and REVIEWER
14. THESIS
15. SCIENTIFIC SOCIETIES MEMBERSHIP
16. LANGUAGES
C. Vitae Jordi Monés 2
PERSONAL DATA:
Name: Jordi Manel Monés i Carilla (Jordi M. Monés)
Address: Institut de la Màcula
Centro Médico Teknon
Àrea Vilana. Building 90
Vilana 12, 08022 Barcelona SPAIN
Telephone +34 93 5950155
Fax +34 93 5950345
E- mail: [email protected]
Web: www.institutmacula.com
Date of Birth: Barcelona, June 25, 1961.
1. EDUCATION / QUALIFICATIONS:
1.1. 09/1979 - 06/1985: LICENCIATE IN MEDICINE AND SURGERY.
Qualification: Excellent. University of Barcelona. Barcelona, SPAIN.
1.2. 01/1986: SPANISH NATIONAL BOARD EXAMINATION for a Residency
Position M.I.R.1985/6: National classification number: 84.
1.3. 1/86 - 12/1989: RESIDENCY IN OPHTHALMOLOGY, (Opthalmologist
M.I.R.) Barraquer Institute, Barcelona, SPAIN.
1.4. 1/1990 - 06/1991: RESEARCH FELLOWSHIP IN OPHTHALMOLOGY
(RETINA SERVICE). The Massachusetts Eye and Ear Infirmary, Harvard
University. Boston, U.S.A.
C. Vitae Jordi Monés 3
1.5. 07/1991 - 07/1992: SURGICAL VITREORETINAL FELLOWSHIP. CLINICAL
AND SURGICAL RETINA FELLOWSHIP. Retina Department, Hospital San
José. Instituto Tecnológico y de Estudios Superiores de Monterrey (ITESM).
Monterrey, MEXICO.
1.6. 06/2010 - 06/2012: DOCTORAL THESIS, Ph.D. Degree. DOCTOR IN
MEDICINE AND SURGERY, Qualification: Cum Laude. University of
Barcelona, SPAIN.
2. PRESENT PROFESSIONAL POSITIONS:
2.1. CURRENT:
2.1.1. M.D., Ph.D., Opthalmologist, Macula and Vitreorretinal Specialist and
Researcher.
2.1.1.1. Founder and Director of the Institut de la Màcula Centro Médico
Teknon, Àrea Vilana, Building 90, Vilana 12, 08022 Barcelona, since
2007.
2.1.1.2. Director, principal investigator and one of the founders of the
Barcelona Macula Foundation: Research for Vision, since 2011.
2.1.1.3. Elected Coordinator of the Specialty of Ophthalmology at the
Centro Médico Teknon, since 2010
2.1.1.4. Institut de la Màcula i de la Retina Acredited site of the network
of excellence in research, European Vision Institute
www.europeanvisioninstitute.org/
2.1.1.5. Member of the Steering Committee at the International
Multicenter Clinical Trials Proxima A and Proxima B on Geographic
Atrophy. Roche, Basel, Switzerland
2.1.1.6. Member of the Steering Committee at the International Multicenter Clinical Trials Brighter and Crystal. Novartis.
C. Vitae Jordi Monés 4
2.1.2. Scientific Advisory Boards
2.1.2.1. Member of the Scientific Advisory Board of AMD international
Alliance
2.1.2.2. Member of the Region Europe Ophthalmics Network (REONET)
advisory board, Novartis
2.1.2.3. Member of the European Advisory Board on Retinal Vein
Occlusion, ERAB, Allergan Inc
2.1.2.4. Scientific Advisor of Opththech Inc, New York USA
2.1.2.5. Scientific Advisor of Notalvision Inc, Tel Aviv, Israel
2.1.2.6. Member of the International Advisory Board for Eylea® (VEGF-
Trap eye) Bayer Schering Pharma
2.1.3. Other positions:
2.1.3.1. Member of the Board of Directors of Futbol Club Barcelona and
Responsible of the Medical Department and Performance from 2003-
2005, and 2010-2015.
2.1.3.2. Member of the Board of Directors, Comissioner FC Barcelona
Universitas and Responsible for the Sport Sciences Department,
since 2015.
3. PAST POSITIONS:
Consultant as Vitreoretinal Specialist Ophthalmologist in:
3.1. Institut de Microcirurgía Ocular de Barcelona. (April 1993 -December 2006)
3.2. Hospital de la Creu Roja de Barcelona (1995 - Nov 2004), Consultant
Ophthalmology Service. Vitreoretinal Surgery.
3.3. Associate Profesor Universitat Autònoma de Barcelona in: (2003 - 2006)
Cátedra (Professorship) Institut de Microcirurgia Ocular de Barcelona
C. Vitae Jordi Monés 5
Universitat Autónoma de Barcelona
3.4. Member of the Board of Directors (Junta Directiva) of FUTBOL CLUB
BARCELONA. Responsible of the Medical and Sport Medicine Department
of Futbol Club Barcelona. June 03 - June 05
3.5. Elected Coordinator of the Specialty of Ophthalmology at the Centro Médico
Teknon. Feb 10 - Feb 12
Main Fields of professional interests:
His research particular fields of interest are macular diseases, choroidal
neovascularization, macular degeneration, antiangiogenic therapy, anti
PDGF therapy, geographic atrophy, retinal degeneration, retinal transplant,
stems cells, gene therapy, macular edema, and vitreoretinal and macular
surgery.
4. INTERNATIONAL AWARDS:
4.1. Co-Winner of the INTERNATIONAL AWARD OF EXPERIMENTAL
SURGERY Banc de Sabadell, Acadèmia de Medecina de Barcelona, i
Col.legi Oficial de Metges de Barcelona, with the Research Project:
"Photodynamic Therapy of the Experimental Posterior Malignant Melanoma"
(Massachusetts Eye and Ear Infirmary, Harvard University, Boston, USA.
Director of the Project: Evangelos Gragoudas MD). Barcelona, June 18,
1991.
4.2. Premi a la Recerca Científica en DMAE. Associació Discapacitat Visual de
Catalunya. 30 Novembre 2011
4.3. Academy's Achievement Award 2015. American Academy of Ophthalmology.
5. ADVISORY BOARDS AND RESEARCH COMMITTEES
5.1. 1999: Rotating Member of Study Advisory Group of the “Randomized,
Placebo-Controlled, Masked, Multicenter, Phase III b Study of the Treatment
of the Subfoveal Neovascularization Secondary to Age-Related Macular
C. Vitae Jordi Monés 6
Degeneration and pathologic myopia Using Photodynamic Therapy with
Liposomal BPD-MA Verteporfin” Institut de Microcirurgia Ocular de
Barcelona.
5.2. 2000: Rotating Member of Study Advisory Group of the “Photodynamic
Therapy using Verteporfin Study VER, VIO and VIM”. Institut de Microcirurgia
Ocular de Barcelona.
5.3. 2003: Member of the International Consultant Committee for Research in
AMD, Novartis International, Basel, Switzerland.
5.4. 2003 – 2005: Member of the International Council for Research of Retinal
Diseases of Eyetech Co. New York, USA
5.5. 2003 – Ongoing: Scientific Consultant of Notalvision, Co. Tel-Aviv, Israel.
5.6. 2003 – 2006: Member of the Macula Society Research Committee
5.7. 2008 Allergan advisory board. Annual Meeting Association for Research in
vision and ophthalmology, Fort Lauderdale, USA. May 1-5 2008
5.8. 2008 Advisory Board Meeting Ophthotech for new treatments for exudative
and Dry AMD London, 30 and 31 October, London
5.9. 2008 Advisory board Allergan for Posurdex device for the treatment of
macular edema secondary to retinal vein occlusion and diabetic macular
edema. American Academy of Ophthalmology, November 9. Atlanta, USA
5.10. 2008 Advisory Board for Preferential Hyperacuity Perimeter.
Notalvision, Israel.
5.11. (from 2008 please see in section 13.2)
6. COLLABORATIVE EUROPEAN RESEARCH PROJECTS
6.1. 2013- 2016: LITE: Laser imaging Techniques for the anterior and posterior
eye. Institut de Ciències Fotòniques; Istituto Nazionale di Ottica; Istituto di
Fisica Applicata Nello Carrara, Construzione Strumenti Oftalmici and Institut
C. Vitae Jordi Monés 7
de la Màcula i de la Retina (Principal investigator in Catalonia Site). ERANET
Biophotonics. European Comission Financed
6.2. 2015-2016: PRO4VIP: Innovative PROcurement for Visually Impaired People.
European Pre-Commercial Public Procurement (PCP) and Innovative Public
Procurement (IPP) project that forms part of the European Vision 2020
strategy. Coordinated by AQuAS (Generalitat de Catalunya), it enjoys the
participation of the Barcelona Macula Foundation, together with 12 other
institutions from England, the rest of Spain, Denmark, France and Italy.
Financed by H2020.
6.3. 2015-Ongoing: EYE RISK. Exploring the combined role of genetic and non-
genetic factors for developing Age-Related Macular Degeneration: A systems
level analysis of disease subgroups, risk factors, and pathways (EYE-RISK).
Topic PHC-01-2014. Horizon 2020. Coordinated by Eberhard Karls
Universitaet Tuebingen (EKUT), it enjoys the participation of the Barcelona
Macula Foundation, together with 10 other institutions. Financed by H2020.
6.4. 2016- On going. ADVANCE.CAT. Accelerating Development ON Advanced
Teraphies in Catalonia. RIS3CAT communities. The research and innovation
strategy of Catalonia. Generalitat de Catalunya. Financed by FEDER source.
7. BASIC RESEARCH PROJECTS
7.1. 2012 - 2016: Principal Investigator, The geographic atrophy in pig study (the
GAP study): A phase I escalating dose of subretinal sodium iodate: a toxic-
induced animal model of geographic atrophy of RPE and photoreceptors.
Institut de la Màcula i de la Retina, Barcelona Macula Foundation
7.2. 2016- On going: Principal Investigator. Translational Research in regenerative
stem cell therapies for retinal degenrative diseases from the swine animal
model of retinal atrophy to clinical trials in human patients with age-related
macular degeneration, retinitis pigmentosa and Stargardt’s disease.
Barcelona Macula Foundation. Barcelona Macula Foundation (BMF), Centre
C. Vitae Jordi Monés 8
de Medicina Regenerativa de Barcelona (CMRB), Banc de Sang i Teixitis
(BSiT) and Fundación Leitat.
7. CLINICAL TRIALS
7.1. 1989: Principal Investigator of a multicentric, ranndomized, doble-masked
clinical trial with 60 patients enrolled "Diclofenac colirio versus Dexametasona
colirio en el Tratamiento de Estados Inflamatorios no Quirúrgicos del
Segmento Anterior del Ojo sin Infección”. Centre d’Oftalmologia Barraquer.
7.2. 1997 - 2003: Principal Investigator of a “Randomized, Placebo-Controlled,
Masked, Multicenter, Phase III Study of the Treatment of the Subfoveal
Neovascularization Secondary to Age-Related Macular Degeneration Using
Photodynamic Therapy with Liposomal BPD-MA Verteporfin”. Institut de
Microcirurgia Ocular de Barcelona.
7.3. 1998 - 2002: Principal Investigator of a “Randomized, Placebo-Controlled,
Masked, Multicenter, Phase III b Study of the Treatment of the Subfoveal
Neovascularization Secondary to Age-Related Macular Degeneration and
pathologic myopia Using Photodynamic Therapy with Liposomal BPD-MA
Verteporfin”. Institut de Microcirurgia Ocular de Barcelona.
7.4. 2001 - 2004: Principal Investigator of the Study VER: “Multicenter,
Randomized, Parallel Group, Double Mask, Controlled Phase IIIb, 2-year
Study comparing the Efficacy and Safety of VISUDYNETM Therapy with
Early Retreatment to Standard Treatment in Predominantly Classic Subfoveal
Choroidal Neovascularization”. Institut de Microcirurgia Ocular de Barcelona.
7.5. 2001 - 2004: Principal Investigator of the Clinical Trial: “Eyetech
Pharmaceuticals Phase II/III Clinical Trial with Anti-VRGF Pegylated Aptamer
(EYE001) in patients with Exudative Age-Related Macular Degeneration”.
Institut de Microcirurgia Ocular de Barcelona
7.6. 2001: Principal Investigator of the Clinical Trial: Prospective Clinical Trial of
VisionCare Ophthalmic Technologies Inc’s Implantable Miniature Telescope
C. Vitae Jordi Monés 9
(IMTTM) for Patients with Age-Related Macular Degeneration” Institut de
Microcirurgia Ocular de Barcelona.
7.7. 2003 - 2005: Principal Investigator of the Clinical Trial: “An Evaluation of
Safety and Efficacy of Anecortave Acetate Sterile Suspension Following Sub-
Tenon’s Injections for the Inhibition of Neovascularization in Patients With
Exudative Age-Related Macular Degeneration”. Institut de Microcirurgia
Ocular de Barcelona.
7.8. 2004 - 2005: Principal Investigator, Preferential Hyperacuity Perimetry
Evaluation for Treatrment with Photodynamic Therapy of choroidal
neovascularization. Institut de Microcirurgia Ocular de Barcelona.
7.9. 2005 - 2006: Co-Investigator, Estudio multicéntrico, fase III, enmascarado,
aleatorizado, controlado con simulador, con una duración de 6 meses (con
extensión abierta de 6 meses) para evaluar la seguridad y eficacia del
sistema aplicador DEX PS DDS (Sistema de liberacion del fármaco
dexametasona en el segmento posterior) de 700 microgr y 350 microgr en el
tratamiento de pacientes con edema macular después de la oclusión de la
vena central de la retina u oclusión de la rama de la vena central de la retina.
Institut de Microcirurgia Ocular (IMO)
7.10. 2005 - 2006: Principal Investigator, “ENSAYO fase 3B, aleatorizado,
controlado con tratamiento activo, doble ciego, con simulación simple,
multicéntrico, comparativo y de grupos paralelos, para comparar la seguridad
y la eficacia de inyecciones intravítreas de Macugen administradas cada 6
semanas durante 54 semanas (que pueden ampliarse hasta 102 semanas si
está indicado) más terapia fotodinámica (TFD) simulada, frente a Macugen
más TFD con VISUDYNE, en sujetos con neovascularización coroidea
(NVC) subfoveal predominantemente clásico secundaria a la degeneración
macular relacionada con la edad (DMAE)” estudio 206207-009-00
7.11. 2005 - 2006: Co-investigator. VERTA V1. Institut de Microcirurgia
Ocular (IMO), Novartis EudraCT: 2005-001324-36
C. Vitae Jordi Monés 10
7.12. 2005 - 2006: Principal Investigator, Evaluación internacional de la
carga de enfermedad de la degeneración macular exudativa subfoveal
asociada a la edad. Institut de Microcirurgia Ocular (IMO) Pfizer/ Covance
SOA/COV 2627/ BC 100425
7.13. 2005: Principal Investigator, Estudio de fase III, multicéntrico,
aleatorizado, controlado, con doble enmascaramiento de lactato de
escualamina (MSI-1256F) en inyección para el tratamiento de la
neovascularización coroidea subfoveal asociada a degeneración macular
asociada a la edad. Institut de Microcirurgia Ocular (IMO), Genaera
Corporation, MSI-1256F-302
7.14. 2005 -2006: Principal investigator. Ensayo de reducción de riesgo con
acetoato de anecortave (AART) Evaluación de la eficacia y seguridad de la
administración yuxtqexcleral posterior de acetato de anecortave para
suspensión depot ( 15mg o 30mg ), comparado con la administración
sdimulada en pacientes ( participantes en el estudi "A" o en esl estudio "B")
con riesfgo de desarrollar neovasc coroidea (CNV ) con amenaza a la visión
debido a degeneración macular asociada a la edad ( AMD ) Alcon C-02-60
7.15. 2005 - 2006: Pegaptanib en DMAE exudativa temprana comparada con
DMAE exudativa no temprana.
7.16. 2005 - 2006: Ranibizumab Estudio EXCITE en DMAE exudativa
7.17. 2007 - 2009: Ongoing Promoter and Principal Investigator Raneovasc:
ensayo clínico de fase ii, prospectivo, controlado, abierto, aleatorizado con
grupos paralelos para comparar la seguridad y la eficacia del ranibizumab en
monoterapia frente a la combinación con terapia fotodinámica con
verteporfina (TFDV) en pacientes con neovascularización coroidea (NVC)
subfoveal secundaria a la degeneración macular asociada a la edad (DMAE)
7.18. 2008 – 2009: Principal Investigator Estudio de fase 3, aleatorizado,
doble enmascarado, con asignación paralela de bevasiranib sódico
intravítreo administrado cada 8 ó 12 semanas como terapia de
C. Vitae Jordi Monés 11
mantenimiento tras 3 inyecciones de Lucentis®, comparado con monoterapia
con Lucentis® cada 4 semanas en pacientes con Degeneración Macular
Exudativa Asociada a la Edad. Promotor: OPKO Health.
7.19. 2008-2009: Co-investigator Estudio VIEW-2. Estudio de fase 3,
randomizado, doble enmascarado, con grupo control, para evaluar la eficacia
y seguridad de inyecciones intravítreas repetidas de VEGF-Trap en pacientes
con degeneración macular asociada a la edad exudativa. Promotor: Bayer.
Investigadors: Lluis Arias, Jordi Monés
7.20. 2008-2009: Co-investigator Estudio TG-MV-007. Estudio de fase 3,
multicéntrico, con doble enmascaramiento, controlado con placebo y
aleatorizado de la inyección intravítrea de microplasmina para el tratamiento
no quirúrgico de la adherencia vitreomacular focal. Promotor:
Thrombogenics. Investigadors: Lluis Arias, Jordi Monés
7.21. 2009: Principal investigator and protocol co-designer. A phase 1 study
to establish the safety and tolerability of ARC1905 (anti-c5 aptamer) in
subjects with dry age-related macular degeneration. Principal investigator:
Jordi Monés. Co-investigators: Lluis Arias, Marc Biarnés.
7.22. 2010: Principal investigator and protocol co-designer: An open-labeL
investigator research grant trial Phase II to establish the safety of intravitreous
injections of E10030 (anti-PDGF pegylated aptamer) given in combination
with Lucentis® in NON RESPONDERS subjects with neovascular age-related
macular degeneration. Protocol Number – E10030-001. Investigators: Jordi
Monés
7.23. 2010: Principal investigator “Ensayo Fase II, randomizado, doble
enmascarado, controlado, para establecer la seguridad y la eficacia de
inyecciones intravítreas de E10030 (aptámero pegilado anti-PDGF)
administrado en combinación con Lucentis® en sujetos con Degeneración
Macular Asociada a la Edad forma Neovascular”. Protocolo nº OPH 1001
C. Vitae Jordi Monés 12
7.24. 2010 – Completed: Principal investigator principal & co-designer
protocol – An open-label investigator research grant trial to establish the
safety of intravitreous injections of E10030 (ANTI-PDGF aptamer) given in
combination with Lucentis® in subjects with neovascular age-related macular
degeneration. Protocol E10030-001.
7.25. 2011 – Completed: Principal Investigator. Pilot phase II clinical trial to
evaluate the safety of human fetal retinal transplant in the treatment of
geographic secondary to age-related macular degeneration and retinitis
pigmentosa. Institut de la Màcula i de la Retina, Barcelona Macula
Foundation.
7.26. 2011- 2016: Principal Investigator and Steering committee member
Crystal: A 24-month, phase IIIb, open-label, single arm, multicenter study
assessing the efficacy and safety of individualized, stabilization criteria-driven
pro re rata (PRN) dosing regimen with 0.5-mg ranibizumab intravitreal
injections applied as monotherapy to patients with visual impairment due to
macular edema secondary to central retinal vein occlusion (CRVO).
Promotor: Novartis. Institut de la Màcula i de la Retina, Barcelona Macula
Foundation.
7.27. 2011- 2016: Principal Investigator and Steering committee member
Brighter: A 24-month, phase IIIb, randomized, active-controlled, three-arm,
multicenter study assessing the efficacy and safety of an individualized,
stabilization criteria driven PRN dosing regimen with 0.5 mg ranibizumab
intravitreal injections applied as monotherapy or with adjunctive laser
photocoagulation in comparison to laser photocoagulation in patients with
visual impairment due to macular edema secondary to branch retinal vein
occlusion (BRVO). Promotor: Novartis. Institut de la Màcula i de la Retina,
Barcelona Macula Foundation.
7.28. 2013 - 2016: Principal Investigator. A phase II randomized, double-
mask study to establish the safety and efficacy of high-dose oral Omega 3 in
subjects with high-risk drusen secondary to dry age-related macular
C. Vitae Jordi Monés 13
degeneration. Institut de la Màcula i de la Retina, Barcelona Macula
Foundation.
7.29. 2013 – 2016: Principal Investigator. A phase II randomized, double-
mask study to establish the safety and efficacy of high-dose oral Omega 3 in
subjects with geographic secondary to dry age-related macular degeneration.
Institut de la Màcula i de la Retina, Barcelona Macula Foundation.
7.30. 2012 - 2016: Principal Investigator, The MPL4 Drusen Study. a phase I
study to establish the safety and efficacy of retinal pigment epithelium
Micropulse Laser in subjects with high-risk drusen secondary to age-related
macular degeneration. Institut de la Màcula i de la Retina, Barcelona Macula
Foundation
7.31. 2012- 2016: Principal Investigator, The MPL4 Dry Study. A phase I
study to establish the safety and efficacy of retinal pigment epithelium
Micropulse Laser in subjects with geographic atrophy secondary to dry age-
related macular degeneration. Institut de la Màcula i de la Retina, Barcelona
Macula Foundation
7.32. 2013- 2015. Principal Investigator. Study Macbeth. Ensayo Clínico fase
IV para evaluar la eficacia de Aflibercept en pacientes con degenración
mcular ascoiada a la edad (DMAE) neovascular, sin respuesta óptima a
repetidas inyecciones mensuales intravitreas de anti VEGFA. Promotor:
Bayer.
7.33. 2014- 2016: Principal investigator. Eclipse. A phase 3 Randomized,
doubled masked, controlled trial to establish the safety and efficay of
intravitreous administrarion of FOVISTA (anti-PDGF-b pegylated aptamer)
administered in combination with Lucentis compared to Lucentis Monotherapy
in subjects with suffoveal neovascular age-related macular degeneration.
Multicenter clinical trial. Promotor:Ophthtech Parexel.
7.34. 2014- 2016: Principal Investigator. In Eye- Study. Ensayo Clínico en
fase IV, abiero, aleatorizado, de 3 brazos, multicéntrico y de 12 meses de
C. Vitae Jordi Monés 14
duración, para evaluar la eficacia y seguridad de dos régimenes de
tratamiento, bimensual o PRN flexible individualizado de “tratar y extender”,
versus un régimen PRN según citerios de establización mediante
evaluaciones mensuales de inyecciones intravítreas de Ranibizumab 0.5mg
en pacientes naive con neovascularización coroidea secundaria a la DMAE.
Promotor: SERV.
7.35. 2014- 2015: Principal Investigator. Trend Study. Estudio fase IIIB
multicentrico, randommizado, de 12 meses de seguimiento con evaluador de
la agudeza visual enmascarado para evaluar la eficacia y la seguridad de
Ranibizumab 0.5mg en un régimen de tratar y extender comparado con un
régimen mensual, en pacientes con degeneración mcular neoovascular
asociada a la edad. Promotor: Novartis.
7.36. 2014- Ongoing: Principal Investigator. Assessment of anatomical and
functional outcomes in patients treated with ocriplasmin for vitreomacular
traction/symptomatic vitreomacular adhesion. Multicenter trial. Promotor:
Alcon.
7.37. 2014- Ongoing: Principal Investigator. Study MegaOmega4Dry. A
phase II randomized, double-mask study to establish the safety and efficacy
of High-dose oral Omega 3 in subjects with macular degeneration. Institut de
la Màcula i de la Retina, Barcelona Macula Foundation.
7.38. 2015-Ongoing: DARK. Deterioration of the Dark adaptation function in
patients with drusen. Estudio Observacional Transversal. Institut De La
Màcula and Barcelona Macula Foundation.
7.39. 2015-Ongoing: HARRIER (RTH258–C002). Estudi fase III, multicèntric,
randomitzat, amb doble emmascarament de dos anys de durada que pretén
avaluar l’eficàcia i la seguretat de RTH258 6 mg en comparació amb
aflibercept (EYLEA) en subjectes amb DMAE exsudativa.
7.40. 2016- On going. Omaspect. A multicenter, open-label extensión study
to evaluate the long-term safety and tolerability of Lampalizumab in patients
C. Vitae Jordi Monés 15
with GA secondary to AMD who have completed a Roche-sponsored study.
8. GRANTS:
8.1. FUNDACIÓN RICH (Madrid, Spain): Year 1990, 1.700.000 ptas for 1 year of
Vitreoretinal Researh Fellowship in the Massachusetts Eye and Ear Infirmary,
Harvard University, Boston USA.
8.2. Beca FISS, Ministerio de Sanidad y Consumo. 1991.
9. SCIENTIFIC PUBLICATIONS:
9.1. Editor/Author Book:
9.1.1. Degeneración Macular Asociada a la Edad. J Monés, F Gómez Ulla
(eds) Barcelona, Prous Science, 2005.
9.2. Autor Book Chapters:
9.2.1. Monés i Carilla J, Friedman E: Angiografia coroidea con indocianina
verde en la degeneración macular asociada con la edad. In: La Mácula
Senil. Gómez-Ulla F (ed). Ciba Visión, Barcelona, 5: 75, 1993.
9.2.2. Monés JM, Guyer DR, Puliafito CP: Indocyanine green angiography.
In: Principles and Practice of Ophthalmology. Albert DM, Jakobiec FA
(eds). Philadelphia, WB Saunders, (2) 52: 718, 1994.
9.2.3. Monés i Carilla J: Videoangiografía con indocianina verde mediante
Scanning Laser Ophthalmoscope: Generalidades. In: Nuevos Métodos
de Exploración retiniana. Gómez-Ulla F (ed). Sociedad Española de
Oftalmología, Madrid, 3: 37, 1994.
9.2.4. Monés i Carilla J: Videoangiografía con indocianina verde mediante
C. Vitae Jordi Monés 16
Scanning Laser Ophthalmoscope en la DMAE. In: Nuevos Métodos de
Exploración retiniana. Gómez-Ulla F (ed). Sociedad Española de
Oftalmología, Madrid, 6: 67, 1994.
9.2.5. Monés JM, Slakter J: Indocyanine Videoangiography in Serpiginous
Choroidopathy. IN: Indocyanine Green Angiography. Yannuzzi LA,
Flowe RW, Slakter JS. St. Louis, Mosby, (17): 247, 1997.
9.2.6. Monés JM. Luxación posterior de lentes intraoculares. In: Corcóstegui
B (Eds) Sociedad Española de Oftalmología. Torremolinos, September
1999
9.2.7. Monés JM, Guyer DR, Puliafito CP: Indocyanine green angiography.
In: Principles and Practice of Ophthalmology. 2nd edition Albert DM,
Jakobiec FA (eds). Philadelphia, WB Saunders, (2) 52: 718, 1999.
9.2.8. Monés JM. PDT for miopía. In: Photodynamic Therapy of Ocular
Diseases. Gragoudas ES, Miller JW, Zografos L (eds). Lippincot,
Williams & Wilkins. Philadelplhia
9.2.9. Monés JM, Loewenstein A. Perimetría de Hiperagudeza Preferencial.
In: Degeneración Macular Asociada a la Edad. J Monés, F Gómez Ulla
(eds) Barcelona, Prous Science, 2005.
9.2.10. Arias L, Monés JM. Terapia Fotodinámica em DMAE. In:
Degeneración Macular Asociada a la Edad. J Monés, F Gómez Ulla (eds)
Barcelona, Prous Science, 2005.
9.2.11. Mateo C, Pérez Belmonte L, Navarro R, Monés J. Translocación
macular. In: Degeneración Macular Asociada a la Edad. J Monés, F
Gómez Ulla (eds) Barcelona, Prous Science, 2005.
9.2.12. Monés JM, Guyer DR, Puliafito CP. Indocyanine green
angiography. In: Principles and Practice of Ophthalmology. Albert DM,
Jakobiec FA (eds). 2nd edition Philadelphia, WB Saunders, 2007
9.2.13. Fundus autofluorescence patterns and optical coherence
C. Vitae Jordi Monés 17
tomography in geographic atrophy secondary to AMD"AMD. Revision
book". Silva R et al. Ed Théa, 2010 (at the publisher)
9.2.14. Jonas J, Paques M, Monés J, Glacet-Bernard A. Retinal Vein
Occlusion. Macular Edema. Ed. Gab riel Coscas (at the publisher)
9.2.15. Loewenstein A, Zur D, Tufail A, Monés J. Postsurgical cystoid
macular edema. Retinal Vein Occlusion. Macular Edema. Ed. Gabriel
Coscas (at the publisher)
9.3. Spanish Scientific Journals:
9.3.1. Vilaplana i Blanch D, Soler i Tomàs JR, Monés i Carilla JM, Sena i
Dutrenit JM. Profilaxis del desprendimiento de la retina. Fotocoagulación
con làser. Revista d'Or d'Oftalmologia, 1988.
9.3.2. Soler i Tomàs JR, Vilaplana i Blanch D, Monés i Carilla JM, Sena i
Dutrenit JM. Estudio comparativo làser Argon versus Krypton rojo en el
tratamiento de la coroidorretinopatía central serosa. Revista d'Or
d'Oftalmologia, 1989.
9.4. International Scientific Journals:
9.4.1. Monés JM, Woods WJ, Puliafito CA. Retinal toxicity of hyaluronidase
and thimerosal injected into the vitreous body of the rabbit. Invest
Ophthalmol Vis Sci 32 (4) (Suppl): 879, 1991.
9.4.2. Bauman WC, Monés JM, Tritten JJ, Lin CP, Gragoudas E, Puliafito
CA. Transpupillary phthalocyanine photodynamic therapy of experimental
posterior malignant melanoma. Invest Ophthalmol Vis Sci 32 (4) (Suppl):
713, 1991.
9.4.3. Puliafito CA, Guyer DR, Monés JM, Weaver Y. Indocyanine-Green
Digital Angiography and Dye-Enhanced Diode Laser Photocoagulation of
C. Vitae Jordi Monés 18
Choroidal Neovascularization. Invest Ophthalmol Vis Sci 32 (4) (Suppl):
712, 1991.
9.4.4. Guyer DR, Puliafito CA, Monés JM, et al. Indocyanine-green digital
angiography in chorioretinal disorders. Ophthalmol 99: 287, 1992.
9.4.5. Corcóstegui B, Monés JM. Indocyanine videangiography with Scanning
Laser Ophthalmoscope of large choroidal vessels in exudative age-
related macular degeneration. Invest Ophthalmol Vis Sci 35 (4) (Suppl):
1507, 1994.
9.4.6. Monés J and the VIP Study Group. Photodynamic therapy (PDT) with
Verteporfin of subfoveal choroidal neovascularization in age-related
macular degeneration: Study design and baseline characteristics in the
VIP randomized clinical trial. Invest Ophthalmol Vis Sci 40 (4) (Suppl):
1703 1999.
9.4.7. TAP Study Group (Jordi Monés is the writing Committee). Treatment of
Age-related Macular Degeneration with Photodynamic Therapy (TAP)
Study Group: Photodynamic Therapy of Subfoveal Choroidal
Neovascularization in Age-Related Macular Degeneration with
Verteporfin. One-Year Results of 2 Randomized Clinical Trials – TAP
Report 1. Arch Ophthalmol 1999; 117: 1329 – 1345.
9.4.8. TAP Study Group (Jordi Monés as is the writing Committee). Case
series of VA improvements following PDT with Verteporfin fon CNV in
AMD (In preparation)
9.4.9. TAP Study Group (Jordi Monés as is the writing Committee).
Photodynamic therapy of subfoveal choroidal neovascularization in age-
related macular degeneration with verteporfin: two-year results of 2
randomized clinical trials-tap report 2. Arch Ophthalmol 2001
Feb;119(2):198-207.
9.4.10. VIP Study Group (Jordi Monés as is the writing Committee).
C. Vitae Jordi Monés 19
Photodynamic Therapy of Subfoveal Choroidal Neovascularization in
Pathologic Myopia with Verteporfin. Two-year Vision Results of 2
Randomized Clinical Trials. VIP report 1. Ophthalmology 2001
May;108(5):841-852
9.4.11. VIP Study Group (Jordi Monés as is the writing Committee).
Verteporfin Therapy of Subfoveal choroidal neovascularization in age-
related macular degeneration: two-year results of a randomised clinical
trial including lesions with occult with no classic choroidal
neovascularization – verteporfin in photodynamic therapy report 2. Am J
Ophthalmol 2001 May, 131 (5): 541-560.
9.4.12. Verteporfin Roundtable 2000 and 2001 Participants; Treatment
of age-related macular degeneration with photodynamic therapy (TAP)
study group principal investigators; Verteporfin in photodynamic therapy
(VIP) study group principal investigators. Guidelines for using verteporfin
(visudyne) in photodynamic therapy to treat choroidal neovascularization
due to age-related macular degeneration and other causes. Retina. 2002
Feb;22(1):6-18.
9.4.13. VIP Study Group (Jordi Monés as is the writing Committee).
Letter to the Editor of the American Journal of Ophthalmology regarding
additional data relevant to VIP Report 2.
9.4.14. Blumenkranz MS, Bressler NM, Bressler SB, Donati G, Fish GE,
Haynes LA, Lewis H, Miller JW, Mones JM, Potter MJ, Pournaras C,
Reaves A, Rosenfeld PJ, Schachat AP, Schmidt-Erfurth U, Sickenburg M,
Singerman LJ, Slakter JS, Strong A, Vannier S; Treatment of Age-
Related Macular Degeneration with Photodynamic Therapy (TAP) Study
Group.Verteporfin therapy for subfoveal choroidal neovascularization in
age-related macular degeneration: three-year results of an open-label
extension of 2 randomized clinical trials--TAP Report no. 5. Arch
Ophthalmol. 2002 Oct;120(10):1307-14.
C. Vitae Jordi Monés 20
9.4.15. Bressler NM, Arnold J, Benchaboune M, Blumenkranz MS, Fish
GE, Gragoudas ES, Lewis H, Schmidt-Erfurth U, Slakter JS, Bressler SB,
Manos K, Hao Y, Hayes L, Koester J, Reaves A, Strong HA; Treatment of
Age-Related Macular Degeneration with Photodynamic Therapy (TAP)
Study Group. Verteporfin therapy of subfoveal choroidal
neovascularization in patients with age-related macular degeneration:
additional information regarding baseline lesion composition's impact on
vision outcomes-TAP report No. 3. Arch Ophthalmol. 2002
Nov;120(11):1443-54
9.4.16. Barbazetto I, Burdan A, Bressler NM, Bressler SB, Haynes L,
Kapetanios AD, Lukas J, Olsen K, Potter M, Reaves A, Rosenfeld P,
Schachat AP, Strong HA, Wenkenstern A; Treatment of Age-Related
Macular Degeneration with Photodynamic Therapy Study Group;
Verteporfin in Photodynamic Therapy Study Group. Photodynamic
therapy of subfoveal choroidal neovascularization with verteporfin:
fluorescein angiographic guidelines for evaluation and treatment--TAP
and VIP report No. 2. Arch Ophthalmol. 2003 Sep;121(9):1253-68
9.4.17. Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato
G, Lewis H, Lim JI, Menchini U, Miller JW, Monés JM, Potter MJ,
Pournaras C, Reaves A, Rosenfeld P, Schachat AP, Schmidt-Erfurth U,
Sickenberg M, Singerman LJ, Slakter JS, Strong HA, Virgili G, Williams
GA. Verteporfin therapy of subfoveal choroidal neovascularization in
pathologic myopia: 2-year results of a randomized clinical trial-VIP report
no. 3. Ophthalmology. 2003 Apr;110(4):667-73.
9.4.18. TAP Study Group (Jordi Monés as is the writing Committee).
Blinder KJ, Bradley S, Bressler NM, Bressler SB, Donati G, Hao Y, Ma C,
Menchini U, Miller J, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ,
Strong HA, Stur M, Su XY, Virgili G; Treatment of Age-related Macular
Degeneration with Photodynamic Therapy study group; Verteporfin in
Photodynamic Therapy study group. Effect of lesion size, visual acuity,
C. Vitae Jordi Monés 21
and lesion composition on visual acuity change with and without
verteporfin therapy for choroidal neovascularization secondary to age-
related macular degeneration: TAP and VIP report no. 1. Am J
Ophthalmol. 2003 Sep;136(3):407-18
9.4.19. Azab M, Benchaboune M, Blinder KJ, Bressler NM, Bressler SB,
Gragoudas ES, Fish GE, Hao Y, Haynes L, Lim JI, Menchini U, Miller JW,
Monés J, Potter MJ, Reaves A, Rosenfeld PJ, Strong A, Su XY, Slakter
JS, Schmidt-Erfurth U, Sorenson JA; Treatment of Age-Related Macular
Degeneration with Photodynamic Therapy (TAP) Study Group;
Verteporfin in Photodynamic Therapy (VIP) Study GroupVerteporfin
therapy of subfoveal choroidal neovascularization in age-related macular
degeneration: meta-analysis of 2-year safety results in three randomized
clinical trials: Treatment Of Age-Related Macular Degeneration With
Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study.
Report no. 4. Retina. 2004 Feb;24(1):1-12.
9.4.20. (Jordi Monés as in the Writing Committee). Pegaptanib for
Neovascular Age-Related Macular Degeneration. Evangelos S.
Gragoudas, M.D., Anthony P. Adamis, M.D.,Emmett T. Cunningham, Jr.,
M.D., Ph.D., M.P.H., Matthew Feinsod, M.D.,and David R. Guyer, M.D.,
for the VEGF Inhibition Study in Ocular Neovascularization Clinical Trial
Group. n engl j med 351;27 www.nejm.org December 30, 2004
9.4.21. Monés J, Rubin GS. Contrast sensitivity as an outcome
measure in patients with subfoveal choroidal neovascularisation due to
age-related macular degeneration. Eye (Lond). 2005 Nov;19(11):1142-50.
Review.
9.4.22. TAP Study Group (Jordi Monés as in the writing Committee).
Verteporfin Therapy for Subfoveal Choroidal Neovascularization in Age-
Related Macular Degeneration: Four-Year Results of an Open-Label
Extension of 2 Randomized Clinical Trials: TAP Report No. 7 Arch
Ophthalmol. 2005;123:1283-1285.
C. Vitae Jordi Monés 22
9.4.23. Chakravarthy U, Soubrane G, Bandello F, Chong V, Creuzot-
Garcher C, Dimitrakos SA 2nd, Korobelnik JF, Larsen M, Monés J,
Pauleikhoff D, PournarasCJ, Staurenghi G, Virgili G, Wolf S. Evolving
European guidance on the medical management of neovascular age
related macular degeneration.Br J Ophthalmol. 2006 Sep;90(9):1188-96.
9.4.24. Monés J. New perspectives on the treatment of age-related
macular degeneration. Drugs Today (Barc). 2005 Nov;41(11):701.
9.4.25. Monés JM, Lopez MA, Prieto JA, Rodriguez JP.Extrafoveal
choroidal neovascularization secondary to wet age-related macular
degeneration treated with intravitreal bevacizumab.Ophthalmic Surg
Lasers Imaging. 2007 May-Jun;38(3):226-8.
9.4.26. Monés J [Bevacizumab or Ranibizumab, or the tale of Robin
Hood and King Richard Lion Heart.]Arch Soc Esp Oftalmol. 2007
Sep;82(9):529-30. Spanish. No abstract available. PMID: 17846939
[PubMed - in process]
9.4.27. Soubrane G, Cruess A, Lotery A, Pauleikhoff D, Monés J, Xu X,
Zlateva G, Buggage R, Conlon J, Goss TF. Burden and health care
resource utilization in neovascular age-related macular degeneration:
findings of a multicountry study. Arch Ophthalmol. 2007 Sep;125(9):1249-
54.
9.4.28. Cruess AF, Zlateva G, Xu X, Soubrane G, Pauleikhoff D, Lotery
A, Monés J, Buggage R, Schaefer C, Knight T, Goss TF. Economic
burden of bilateral neovascular age-related macular degeneration: multi-
country observational study. Pharmacoeconomics. 2008;26(1):57-73.
9.4.29. Monés J, Amselem L, Serrano A, García M, Hijano M.
Intravitreal ranibizumab for choroidal neovascularization secondary to
pathologic myopia: 12-month results. Eye. 2009 Jun;23(6):1275-80
C. Vitae Jordi Monés 23
9.4.30. Amselem L, Pulido JS, Gunduz K, García-Arumí J, Monés J.
Infrared reflectance in choroidal melanomas and its correlation with
fundus autofluorescence. Br J Ophthalmol. 2008 Nov;92(11):1565-6.
[Pubmed]
9.4.31. Ruiz-Moreno JM, Arias-Barquet L, Armadá-Maresca F,
Boixadera-Espax A, García-Layana A, Gómez-Ulla-de-Irazazábal F,
Monés-Carilla J, Piñero-Bustamante A, Suárez-de-Figueroa M.
[Guidelines of clinical practice of the SERV: treatment of exudative age-
related macular degeneration (AMD)] Arch Soc Esp Oftalmol. 2009
Jul;84(7):333-44.
9.4.32. Arias L. Monés J. Transconjunctival sutureless vitrectomy with
tissue plasminogen activator, gas and intravitreal bevacizumab in the
management of predominantly hemorrhagic age-related macular
degeneration. Clinical Ophthalmology 2010: 4 67-72
9.4.33. Arias L, Monés J. Ranibizumab in the treatment of choroidal
neovascularization on the border of an inferior staphyloma associated
with tilted disc syndrome. Clin Ophthalmol. 2010 Apr 26;4:227-31.
9.4.34. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M,
Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup
SM; OZURDEX GENEVA Study Group. ( Jordi Monés as in the GENEVA
Study Group). Randomized, sham-controlled trial of dexamethasone
intravitreal implant in patients with macular edema due to retinal vein
occlusion. Ophthalmology. 2010 Jun;117(6):1134-1146.e3. Epub 2010
Apr 24
9.4.35. Jonas J, Paques M, Monés J, Glacet-Bernard A. Retinal vein
occlusions. Dev Ophthalmol. 2010;47:111-35. Epub 2010 Aug 10.
Review.
9.4.36. Biarnés M, Monés J, Villalbí JR, Arias L. As-needed treatment
with ranibizumab 0.5 mg in patients with neovascular age-related macular
C. Vitae Jordi Monés 24
degeneration. Eur J Ophthalmol. 2011 May-Jun;21(3):282-9. doi:
10.5301/EJO.2010.5766. PMID: 20890885 [PubMed - indexed for
MEDLINE]
9.4.37. Monés J. A Review of Ranibizumab Clinical Trial Data in
Exudative Age-Related Macular Degeneration and How to Translate It
into Daily Practice. Ophthalmologica. 2011;225(2):112-9. doi:
10.1159/000319906. Epub 2010 Oct 8.
9.4.38. Zur D, Fischer N, Tufail A, Monés J, Loewenstein A.Postsurgical
cystoid macular edema. Eur J Ophthalmol. 2011;21 Suppl 6:S62-8. doi:
10.5301/EJO.2010.6058.
9.4.39. Biarnés M, Monés J, Arias L, Villalbí JR. An Update on
Geographic Atrophy in Age-Related Macular Degeneration Optometry
and Vision Science. Optometry and Vision Science. Optom Vis Sci. 2011
Apr 28. [Epub ahead of print]
9.4.40. Coscas G, Loewenstein A, Augustin A, Bandello F, Battaglia M,
Lanzetta P, Monés J, de Smet M, Soubrane G, Staurenghi G.
Management of Retinal Vein Occlusion – Consensus Document.
Ophthalmologica 2011;226:4-28.
9.4.41. Biarnés M, Monés J, Trindade F, Alonso J, Arias L. Intra and
interobserver agreement in the classification of fundus autofluorescence
patterns in geographic atrophy secondary to age-related macular
degeneration Graefes Arch Clin Exp Ophthalmol. 2012 Apr;250(4):485-
90. Epub 2011 Oct 28.
9.4.42. Monés J, Biarnés M, Trindade F. Hyporeflective wedge-shaped band
in geographic atrophy secondary to age-related macular degeneration: an
underreported finding. Ophthalmology. 2012 Jul;119(7):1412-9. Epub 2012
Mar 21.
C. Vitae Jordi Monés 25
9.4.43. Monés J, Biarnés M, Trindade F, Casaroli-Marano R. FUSION
regimen: ranibizumab in treatment-naïve patients with exudative age-
related macular degeneration and relatively good baseline visual acuity.
Graefes Arch Clin Exp Ophthalmol. 2012 Dec;250(12):1737-44. Epub
2012 Apr 15.
9.4.44. Monés J, Biarnés M, Trindade F, Arias L, Alonso J. Optical
Coherence Tomography Assessment of Apparent Foveal Swelling in
Ophthalmology. 2013 Apr;120(4):829-36. doi: 10.1016/j.ophtha.2012.
09.054. Epub 2013 Jan 3.
9.4.45. L. Arias Barquet and J. Monés. New treatment protocols and
follow-up in patients with exudative age-related macular degeneration.
Archivos de la Sociedad Española de Oftalmología. Volume 87.
Supplement 1. December 2012.
9.4.46. Lanzetta P. Holz F. Monés J. Querques G. Stanga P. Veritti D.
Barbone F. Brusaferro S. Isola M. Intravitreal Injections: A Healthcare
Failure Modes and Effects Analysis. Ophthalmologica (DOI:
10.1159/000354549).
9.4.47. Monés J, Biarnés M, Badal J. Bimonthly half-dose ranibizumab
in large pigment epithelial detachment and retinal angiomatous
proliferation with high risk of retinal pigment epithelium tear: a case
report. Clin Ophthalmol. 2013;7:1089-92. doi: 10.2147/OPTH.S45155.
Epub 2013 Jun 7.
9.4.48. Monés J. as a participant of a round table of participant leaders.
Advocating for Improved treatment and Outcomes for Wet Age-retaled
Macular Degeneration. A report based on an International Expert Summit.
Convened in Berlin, Germany November 2011. The Angiogenesis
Foundation.
9.4.49. Alfredo García-Layana, Luis Arias, Marta S. Figueroa, Monés J.
Araiz, José María Ruiz-Moreno, José Garcia-Aruní, Francisco Gómez-
C. Vitae Jordi Monés 26
Ulla, María Isabel López-Gálvez, Francisco Cabrera-López, José Manuel
García Campos, Jordi Monés, Enrique Cervera, Félix Armadá, Miguel
Ángle Serrano, Juan Donate, Roberto Gallego-Pinazo. Guía clínica de
Expertos sobre el Manejo de la Degeneración Macular Asociada a la
Edad Exudativa. Revista Española de Patología Macular. Volumen IV.
Nº4. Noviembre de 2013.
9.4.50. Ursula Schmidt-Erfurth, Victor Chong, Anat Loewenstein,
Michael Larsen, Eric Souied, Reinier Schlingemann, Bora Eldem, Jordi
Monés, Gisbert Richard and Francesco Bandello. “Guidelines for the
management of neovascular age-related macular degeneration” by the
European Society of Retina Specialists (EURETINA). The British journal
of ophthalmology 09/2014; 98(9):1144-1167. DOI: 10.1136/bjophthalmol-
2014-305702
9.4.51. Biarnés M, Forero CG, Arias L, Alonso J, Monés J. Reappraisal
of geographic atrophy patterns seen on fundus autofluorescence using a
latent class analysis approach. Invest Ophthalmol Vis Sci. 2014 Nov 18.
pii: IOVS-13-13542. doi: 10.1167/iovs.13-13542. [Epub ahead of print].
9.4.52. Cunha-Vaz J, Ashton P, Iezzi R, Campochiaro P, Dugel PU,
Holz FG, Weber M, Danis RP, Kuppermann BD, Bailey C, Billman K,
Kapik B, Kane F, Green K; FAME Study Group. Monés J. as a
collborator. Sustained delivery fluocinolone acetonide vitreous implants:
long-term benefit in patients with chronic diabetic macular edema.
Ophthalmology. 2014 Oct;121(10):1892-903. doi:
10.1016/j.ophtha.2014.04.019. Epub 2014 Jun 14.
9.4.53. Boyer DS, Goldbaum M, Leys AM, Starita C; V.I.S.I.O.N. Study
Group. Monés J as a collaborator. Effect of pegaptanib sodium 0.3 mg
intravitreal injections (Macugen) in intraocular pressure: posthoc analysis
from V.I.S.I.O.N. study. Br J Ophthalmol. 2014 Nov;98(11):1543-6. doi:
10.1136/bjophthalmol-2013-304075. Epub 2014 Jul 4.
C. Vitae Jordi Monés 27
9.4.54. Gerding H, Monés J, Tadayoni R, Boscia F, Pearce I, Priglinger
S. Ranibizumab in retinal vein occlusion: treatment recommendations by
an expert panel. Br J Ophthalmol. 2014 Jul 29. pii: bjophthalmol-2014-
305041. doi: 10.1136/bjophthalmol-2014-305041. [Epub ahead of print]
9.4.55. García-Layana A, Arias L, Figueroa MS, Araiz J, Ruiz-Moreno
JM, García-Arumí J, Gómez-Ulla F, López-Gálvez MI, Cabrera-López F,
García-Campos JM, Monés J, Cervera E, Armadá F, Gallego-Pinazo R,
Piñero-Bustamante A, Serrano-Garcia M. A delphi study to detect
deficiencies and propose actions in real life treatment of neovascular age-
related macular degeneration. J Ophthalmol. 2014;2014:595132. doi:
10.1155/2014/595132. Epub 2014 Dec 21.
9.4.56. Biarnés M, Arias L, Alonso J, Garcia M, Hijano M, Rodríguez A,
Serrano A, Badal J, Muhtaseb H, Verdaguer P, Monés J. Increased
Fundus Autofluorescence and Progression of Geographic Atrophy
Secondary to Age-Related Macular Degeneration: The GAIN Study. Am J
Ophthalmol. 2015 Aug;160(2):345-353.e5. doi:10.1016/j.ajo.2015.05.009.
Epub 2015 May 15. PMID: 25982972
9.4.57. Freund KB, Korobelnik JF, Devenyi R, Framme C, Galic J,
Herbert E, Hoerauf H, Lanzetta P, Michels S, Mitchell P, Monés J, Regillo
C, Tadayoni R, Talks J, Wolf S. Treat-And-Extend Regimens With Anti-
Vegf Agents in Retinal Diseases: A Literature Review and Consensus
Recommendations. Retina. 2015 Jun 12. [Epub ahead of print]
9.4.58. Dr. Jordi Monés, Dr. Josep Badal, Dr. Marc Biarnés. Feeder
Vessel Laser Photocoagulation For Idiopathic, Subfoveal Polypoidal
Choroidal Vasculopathy Not Responding To Either Anti-Vascular
Endothelial Growth Factor Therapy Or Photodynamic Therapy. Retin
Cases Brief Rep. 2016 Winter;10(1):100-3. doi:
10.1097/ICB.0000000000000174.
C. Vitae Jordi Monés 28
9.4.59. Richard G, Monés J, Wolf S, Korobelnik JF, Guymer R,
Goldstein M, Norenberg C, Sandbrink R, Zeitz O. Scheduled versus Pro
Re Nata Dosing in the VIEW Trials. Ophthalmology. 2015
Dec;122(12):2497-503. doi: 10.1016/j.ophtha.2015.08.014. Epub 2015
Oct 21. PMID: 26477840
9.4.60. Alfredo García-Layana, Marta S. Figueroa, Luis Arias, Javier
Araiz, José María Ruiz-Moreno, José García-Arumí, Francisco Gómez-
Ulla, María Isabel López-Gálvez, Francisco Cabrera-López, José Manuel
García-Campos, Jordi Monés, Enrique Cervera, Felix Armadá, and
Roberto Gallego-Pinazo. Individualized Therapy with Ranibizumab in Wet
Age-Related Macular Degeneration. Journal of Ophthalmology, vol. 2015,
Article ID 412903, 8 pages, 2015. doi:10.1155/2015/412903.
9.4.61. Larsen M, Waldstein SM, Boscia F, Gerding H, Monés J,
Tadayoni R, Priglinger S, Wenzel A, Barnes E, Pilz S, Stubbings W,
Pearce I; CRYSTAL Study Group. Individualized Ranibizumab Regimen
Driven by Stabilization Criteria for Central Retinal Vein Occlusion:
Twelve-Month Results of the CRYSTAL Study. Ophthalmology. 2016
May;123(5):1101-11. doi: 10.1016/j.ophtha.2016.01.011. Epub 2016 Feb
17.
9.4.62. Monés J, Biarnés M. Correspondence. Retina. 2016
Mar;36(3):e20. doi: 10.1097/IAE.0000000000000944. No abstract
available.
9.4.63. Marc Biarnés, PhD; Jordi Monés, MD, PhD. Direct Visualization
of a New Choroidal Vessel on Spectral-Domain Optical Coherence
Tomography. Ophthalmic Images | March 10, 2016. JAMA Ophthalmol.
2016;134(3):e155017. doi:10.1001/jamaophthalmol.2015.5017.
9.4.64. Tadayoni R, Waldstein SM, Boscia F, Gerding H, Pearce I,
Priglinger S, Wenzel A, Barnes E, Gekkieva M, Pilz S, Monés J;
BRIGHTER study group. Individualized Stabilization Criteria-Driven
C. Vitae Jordi Monés 29
Ranibizumab versus Laser in Branch Retinal Vein Occlusion: Six-Month
Results of BRIGHTER. Ophthalmology. 2016 Jun;123(6):1332-44. doi:
10.1016/j.ophtha.2016.02.030. Epub 2016 Mar 30.
9.4.65. Monés J, Leiva M, Peña T, Martínez G, Biarnés M, Garcia M,
Serrano A, Fernandez E. A Swine Model of Selective Geographic Atrophy
of Outer Retinal Layers Mimicking Atrophic AMD: A Phase I Escalating
Dose of Subretinal Sodium Iodate. Invest Ophthalmol Vis Sci. 2016 Aug
1;57(10):3974-83. doi: 10.1167/iovs.16-19355. PMID: 27479813
9.4.66. Jaffe GJ, Ciulla TA, Ciardella AP, Devin F, Dugel PU, Eandi CM,
Masonson H, Monés J, Pearlman JA, Quaranta-El Maftouhi M, Ricci F,
Westby K, Patel SC. Dual Antagonism of PDGF and VEGF in
Neovascular Age-Related Macular Degeneration: A Phase IIb,
Multicenter, Randomized Controlled Trial. Ophthalmology. 2017
Feb;124(2):224-234. doi: 10.1016/j.ophtha.2016.10.010. PMID: 28029445
9.4.67. Holz FG, Sadda SR, Staurenghi G, Lindner M, Bird AC, Blodi
BA, Bottoni F, Chakravarthy U, Chew EY, Csaky K, Curcio CA, Danis R,
Fleckenstein M, Freund KB, Grunwald J, Guymer R, Hoyng CB, Jaffe GJ,
Liakopoulos S, Monés JM, Oishi A, Pauleikhoff D, Rosenfeld PJ, Sarraf
D, Spaide RF, Tadayoni R, Tufail A, Wolf S, Schmitz-Valckenberg S;
CAM group. Imaging Protocols in Clinical Studies in Advanced Age-
Related Macular Degeneration: Recommendations from Classification of
Atrophy Consensus Meetings. Ophthalmology. 2017 Jan 18. pii: S0161-
6420(16)30920-4. doi: 10.1016/j.ophtha.2016.12.002. [Epub ahead of
print] PMID: 28109563
9.4.68. Badal J, Biarnés M, Monés J. Performance characteristics of
multicolor versus blue light and infrared imaging in the identification of
reticular pseudodrusen. Int Ophthalmol. 2017 Jan 21. doi:
10.1007/s10792-017-0448-z. [Epub ahead of print] PMID: 28108901
C. Vitae Jordi Monés 30
9.4.69. Monés, J., Garcia, M., Biarnés, M., Lakkaraju, A., & Ferraro, L.
(2017). Drusen Ooze: A Novel Hypothesis in Geographic Atrophy.
Ophthalmology Retina. Ophthalmology Retina 2017;-:1e13 ª 2017 by the
American Academy of Ophthalmology.
9.4.70. Monés J, Biarnés M. Geographic atrophy phenotype
identification by cluster analysis. British Journal of Ophthalmology.
Published Online First: 20 July 2017. doi: 10.1136/bjophthalmol-2017-
310268
9. SCIENTIFIC PRESENTATIONS:
9.1. Spanish Meetings:
9.1.1. Monés i Carilla JM, Ruiz Bulumar JL.: "Uso de la Mezlocilina tópica en
el Tratamiento del Absceso Corneal por Pseudomonas". "LXIII
CONGRESO NACIONAL DE LA SOCIEDAD ESPAÑOLA DE
OFTALMOLOGIA". Oviedo, September 1987.
9.1.2. Monés JM: "Lesiones predisponentes. Profilaxis del desprendimiento
de la retina". "III CURSO DEL DESPRENDIMIENTO DE RETINA Y
VITREO. INSTITUTO CASTANERA". Barcelona, October 1987.
9.1.3. Monés i Carilla JM, Rodriguez i Prats JL, Iglesias i Touriño E:
"Afectació Ocular en la Neurofibromatosi de Von Reckinghausen". "VII
JORNADES MÈDIQUES DEL VALLÈS. ACADÈMIA DE CIÈNCIES
MÈDIQUES DE CATALUNYA I BALEARS". Sabadell, November 1987.
9.1.4. Monés i Carilla JM, Soler i Tomàs JR, Iglesias i Touriño E: "Tractament
de l'Abscés Cornial Bacterià Resistent als Antibiòtics Convencionals".
"VII JORNADES MÈDIQUES DEL VALLÈS. ACADÈMIA DE
CIÈNCIES MÈDIQUES DE CATALUNYA I BALEARS". Sabadell,
November 1987.
C. Vitae Jordi Monés 31
9.1.5. Vilaplana i Blanch D, Soler i Tomàs JR, Monés i Carilla JM, Sena i
Dutrenit JM: "Fotocoagulació Làser en la Profilaxi del Desprendiment
de la Retina". "VII JORNADES MÈDIQUES DEL VALLÈS. ACADÈMIA
DE CIÈNCIES MÈDIQUES DE CATALUNYA I BALEARS". Sabadell,
November 1987.
9.1.6. Monés i Carilla, JM, Samaan M: "Goniotomía ab interno y
trabeculotomía ab externo con trabeculectomía". "LXIV CONGRESO
DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGIA". Palma de
Mallorca, October 1988.
9.1.7. Monés J, Corcóstegui B: "Videoangiografia amb indocianina verda -
oftalmoscopi de làser d'scanning (VICV - SLO) en la degeneració
macular associada a l'edat (DMAE) forma exudativa." "NOVES
TÉCNIQUES D'EXPLORACIÓ I DIAGNÒSTIC EN OFTALMOLOGIA".
La Seu D'Urgell, April 1994.
9.1.8. Monés J, Corcóstegui B: " Videoangiografia amb indocianina verda -
oftalmoscopi de làser d'scanning (VICV - SLO). Estudi i diagnòstic de
les malalties inflamatòries coroidals." "NOVES TÉCNIQUES
D'EXPLORACIÓ I DIAGNÒSTIC EN OFTALMOLOGIA". La Seu
D'Urgell, April 1994.
9.1.9. Monés J, García Arumí J, Adán A: "Estudio y diagnóstico de las
coroiditis mediante la videongiografía indocianina verde - SLO." "LXX
CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA".
Tenerife, September 1994.
9.1.10. Monés J, Mateo C, Corcóstegui B: "Detección y clasificación de
las membranas neovasculares coroideas en la DMAE mediante
videoangiografía ICV - SLO. "LXX CONGRESO DE LA SOCIEDAD
ESPAÑOLA DE OFTALMOLOGÍA". Tenerife, September 1994.
9.1.11. Monés J, Corcóstegui B, Durán N: "Patrones cicrculatorios
C. Vitae Jordi Monés 32
coroideos submaculares en la DMAE." "LXX CONGRESO DE LA
SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA". Tenerife, September
1994.
9.1.12. Monés J, Corcóstegui B: "Efecte a distància de la
fotocoagulació amb làser de diode: una complicació o una estratègia
terapeútica?" "25è CONGRÉS DE LA SOCIETAT CATALANA
D'OFTALMOLOGIA". Barcelona, December 1994.
9.1.13. Jordi Monés, Andreu Coret: “Técnica combinada de implante
secundario de LIO de cámara posterior por incisión corneal con
vitrectomía pars plana y fijación transescleral”. “III CONGRESO DE LA
SOCIEDAD ESPAÑOLA DE RETINA Y VITREO”. Madrid, February
21-22, 1997.
9.1.14. Jordi Monés, Andreu Coret, Josep Ramon Soler: “Recolocación
interna con fijación escleral de LIO luxada a cámara vítrea mediante
vitrectomía posterior”. “III CONGRESO DE LA SOCIEDAD ESPAÑOLA
DE RETINA Y VITREO”. Madrid, February 21-22, 1997.
9.1.15. Jordi Monés i Carilla, Andreu Coret Novoa: “ Técnica combinada
de cirugía del agujero macular y facoemulsificación e implante de LIO
de CP” “12º CONGRESO SECOIR”. Santander, April 23-26, 1997.
9.1.16. Jordi Monés i Carilla, Josep Ramon Soler i Tomás: “ Técnica de
implante 2ºde LIO-CP con fijación transescleral mediante vitrectomía
posterior.” “12º CONGRESO SECOIR”. Santander, April 23-26, 1997
9.1.17. J. Monés, F. Huste, IH Tercero: “Tècnica d’implant secundari de
LIO amb fixació transescleral amb vitrectomia posterior” “4ª BIENNAL
DE VIDEO OFTALMOLOGIA”. Girona, June 28, 1997.
9.1.18. J. Monés, JR Soler Tomàs, JA Cardona: “Tècnica combinada
de cirurgia de forat macular i facoemulsificació i implant de LIO-CP” “4ª
BIENNAL DE VIDEO OFTALMOLOGIA”. Girona, June 28, 1997.
C. Vitae Jordi Monés 33
9.1.19. Jordi Monés Carilla, Andrés Coret. “Recolocación interna de LIO
luxada a cámara vítrea mediante vitrectomía posterior y fijación
transecleral. LXXIII CONGRESO DE LA SOCIEDAD ESPAÑOLA DE
OFTALMOLOGÍA". Granada, September 24-28, 1997.
9.1.20. José Ramon Soler Tomás, Jordi Monés Carilla. “Técnica
combinada de cirugía de agujero macular y facoemulsificación de la
catarata con implante plegable de cámara posterior”. LXXIII
CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA".
Granada, September 24-28, 1997.
9.1.21. Jordi Monés Carilla. “Vitrectomía posterior sin suturas” 74
CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA.
Alicante, September 30 - October 4, 1998.
9.1.22. Jordi Monés i Carilla “Técnica de reparación inmediata de
luxación de núcleo durante la facoemulsificación: vitrectomía posterior
e implante de lente intraocular con fijación escleral a través de pequeña
incisión”. 74 CONGRESO DE LA SOCIEDAD ESPAÑOLA DE
OFTALMOLOGÍA. Alicante, 30 Sept - Oct 4, 1998.
9.1.23. Jordi Monés: “Terapia Fotodinámica en DAME exudativa:
Resultados de pacientes en Uso compasivo.” ” 76 CONGRESO DE
LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Madrid, 11-15
October, 2000.
9.1.24. Jordi Monés I cols. Teràpia Fotodinàmica en DMAE: resultants de pacients en Fase d’ús Compassiu. 31 CONGRÉS DE LA SOCIETAT CATALANA D’OFTALMOLOGIA”. Barcelona, 23-24 November 2000.
(PRESENTATIONS and LECTURES are presented together from this point in
the section 11.2)
9.2. International Meetings:
C. Vitae Jordi Monés 34
9.2.1. Sena Dutrenit JM, Vilaplana D, Soler JR, Monés JM: "Resultados de la
Fotocoagulación Láser". "IX CURS INTERNACIONAL
D'OFTALMOLOGIA DEL INSTITUT BARRAQUER". Barcelona, May
1987.
9.2.2. David R. Guyer, Carmen A. Puliafito, Jordi M. Monés:
"Indocyanine-Green Digital Angiography and Dye-Enhanced Diode
Laser Photocoagulation of Choroidal Neovascularization".
"ADVANCES IN OCULAR DRUG THERAPY: A PRACTICAL
PERSPECTIVE. Massachusetts Eye and Ear Infirmary. Harvard
Medical School. Boston, Massachusetts. USA, March 9, 1991.
9.2.3. David R. Guyer, Carmen A. Puliafito, Jordi M. Monés:
"Indocyanine-Green Digital Angiography and Dye-Enhanced Diode
Laser Photocoagulation of Choroidal Neovascularization". "1991
WILMER RESIDENTS ASSOCIATION MEETING". THE Wilmer
Institute. John Hopkins University, School of Medicine. Baltimore,
Maryland. USA. April 25-27, 1991.
9.2.4. Wendall C. Bauman, Jordi M. Monés, Jean-Jacques Tritten, Charles P.
Lin, Evangelos Gragoudas, Carmen A. Puliafito: "Transpupillary
Phthalocyanine Photodynamic Therapy of Experimental Posterior
Malignant Melanoma". "1991 ANNUAL MEETING OF THE
ASSOCIATION FOR RESEARCH IN VISION AND
OPHTHALMOLOGY, ARVO". Sarasotta, Florida. USA. April 28 - May
2, 1991.
9.2.5. Jordi M. Monés, William J. Woods and Carmen A Puliafito: "Retinal
Toxicity of Hyaluronidase and Thimerosal injected into the Vitreous
Body of the Rabbit". "1991 ANNUAL MEETING OF THE
ASSOCIATION FOR RESEARCH IN VISION AND
OPHTHALMOLOGY, ARVO". Sarasotta, Florida. USA. April 28 - May
2, 1991.
C. Vitae Jordi Monés 35
9.2.6. Carmen A. Puliafito, David R. Guyer, Jordi M. Monés, Yaffa Weaver:
"Indocyanine-Green Digital Angiography and Dye-Enhanced Diode
Laser Photocoagulation of Choroidal Neovascularization". "1991
ANNUAL MEETING OF THE ASSOCIATION FOR RESEARCH IN
VISION AND OPHTHALMOLOGY, ARVO". Sarasotta, Florida. USA.
April 28-May 2, 1991.
9.2.7. Ephraim Friedman, Jordi M. Monés: "The use of Indocyanine-Green in
evaluating the Choroidal Circulation". "MASSACHUSETTS EYE AND
EAR ALUMNI ASSOCIATION. ANNUAL CLINICAL AND SCIENTIFIC
MEETING". Boston, Massachusetts. USA. May 16,1991.
9.2.8. David R. Guyer, Carmen A. Puliafito, Jordi M. Monés:
"Indocyanine-Green Dye Enhanced Diode Laser Photocoagulation of
Choroidal Neovascularization". "MASSACHUSETTS EYE AND EAR
ALUMNI ASSOCIATION. ANNUAL CLINICAL AND SCIENTIFIC
MEETING". Boston, Massachusetts. USA. May 16,1991.
9.2.9. Wendall C. Bauman, Jean-Jacques Tritten, Jordi M. Monés, Charles P.
Lin, Evangelos Gragoudas, Carmen A. Puliafito: "Transpupillary
PhotodynamicTherapy of Experimental Malignant Melanoma".
"MASSACHUSETTS EYE AND EAR ALUMNI ASSOCIATION.
ANNUAL CLINICAL AND SCIENTIFIC MEETING". Boston,
Massachusetts. USA. May 16,1991.
9.2.10. Jordi M. Monés, David R. Guyer, Carmen A. Puliafito, Ephraim
Friedman. "Indocyanine-Green Angiography in Choroidal Diseases".
"1991 SCHEPENS INTERNATIONAL SOCIETY MEETING". Madrid,
May 27-31, 1991.
9.2.11. Jordi M. Monés, Wendall C. Bauman, Jean-Jacques Tritten,
Charles P. Lin, Carmen A. Puliafito, Evangelos Gragoudas:
"Phthalocyanine Photodynamic Treatment of Experimental Posterior
Malignant Melanoma". "1991 SCHEPENS INTERNATIONAL SOCIETY
C. Vitae Jordi Monés 36
MEETING". Madrid, May 27- 31, 1991.
9.2.12. Carmen A. Puliafito, David R. Guyer, Jordi M. Monés: "Digital
Indocyanine-Green Angiography in retinal vascular diseases". "1991
ANNUAL MEETING OF THE AMERICAN ACADEMY OF
OPHTHALMOLOGY". Anaheim, California. USA. October 13-17,
1991.
9.2.13. Corcóstegui B, Monés JM: "Indocyanine videangiography with
Scanning Laser Ophthalmoscope of large choroidal vessels in
exudative age-related macular degeneration." "1994 ANNUAL
MEETING OF THE ASSOCIATION FOR RESEARCH IN VISION AND
OPHTHALMOLOGY, ARVO". Sarasotta, Florida. USA. May 1-6, 1994.
9.2.14. Jordi M. Monés, Borja Corcóstegui: "Submacular choroidal
vascular patterns in exudative age-related macular degeneration." "4th
INTERNATIONAL SYMPOSIUM ON OCULAR CIRCULATION AND
NEOVASCULARIZATION". Budapest, Hungary, May 22-26, 1995.
9.2.15. Jordi Monés i Carilla, Josep Ramon Soler i Tomàs: “Implante
secundario con fijación transescleral mediante Vitrectomía Posterior”
“CURSO INTERNACIONAL INSTITUTO BARRAQUER”. Barcelona,
June 9-11, 1997.
9.2.16. Jordi Monés, Andreu Coret, Josep Ramon Soler: “Recolocación
interna con fijación escleral de LIO luxada a cámara vítrea mediante
vitrectomía posterior”. “CURSO INTERNACIONAL INSTITUTO
BARRAQUER”. Barcelona, June 9-11, 1997.
9.2.17. JR Soler Tomàs, J Monés, A Cardona, F. Huste: “Anillos
intracapsulares de tensión. Aplicaciones” “CURSO INTERNACIONAL
INSTITUTO BARRAQUER”. Barcelona, June 9-11, 1997.
9.2.18. Monés JM: Pars plana vitrectomy and scleral fixation of foldable
intraocular lens through small incision during complicated
C. Vitae Jordi Monés 37
pahcoemulsification of dense cataract with intravitreal nuclear
fragments luxation. XVIth CONGRESS OF THE ESCRS. Nice,
September 6-9, 1998.
9.2.19. Monés J and the VIP Study Group. Photodynamic therapy
(PDT) with Verteporfin of subfoveal choroidal neovascularization in age-
related macular degeneration: Study design and baseline
characteristics in the VIP randomized clinical trial. Invest Ophthalmol
Vis Sci 40 (4) (Suppl): 1703 1999.
9.2.20. Monés JM. Reunión de casos clínicos: Retina y Vítreo.
Andorra, January 2000.
9.2.21. Monés JM. Principle Aspects of Clinical Trials of Photodynamic
Therapy with Verteporfin (VisudyneTM): Phase I and II, and phase III
(TAP and VIP Study) in the treatment of CNV secondary to AMD y
Pathologic Myopia. International Symposium Ocular Pharmacology.
and Pharmaceutics. Lisbon, February 12, 2000.
9.2.22. Monés JM. One-year Angiographic Outcomes and Safety
Following Photodynamic Therapy with Verteporfin (Visudyne) for
subfoveal choroidal neovascularization in AMD – Results of Two
Randomized Phase III Clinical Trials (TAP Investigation) International
Symposium Ocular Pharmacology. and Pharmaceutics. Lisbon,
February 12, 2000.
9.2.23. Monés JM. One-year Angiographic Outcomes and Safety
Following Photodynamic Therapy with Verteporfin (Visudyne) for
subfoveal choroidal neovascularization in AMD – Results of Two
Randomized Phase III Clinical Trials (TAP Investigation) VI
Mediterranean Ophthalmological Society Congress and VI Michaelson
Symposium on Ocular Circulation and Neovascualrization. Jerusalem,
Israel, May 24, 2000.
C. Vitae Jordi Monés 38
9.2.24. Photodynamic Therapy of Subfoveal Choroidal
Neovascularization in Pathologic Myopia Using Verteporfin
(Visudynetm); One-year Results – VIP Report #1. The Retina Society
33RD Annual Meeting. Coral Gables, FLA, USA, November 30 -
December 3, 2000.
9.2.25. Polypoidal Choroidal Vasculopathy in recurrent CNV after PDT.
The Retina Society 34rd Annual Meeting. Chiacago, USA October 14-
17 2001 (It was going to be presented, Meeting Cancelled due to
September 11th 2001)
9.2.26. Safety of multiple consecutive areas of light application during
treatment of CNV with PDT. Reinaldo Castillo, Javier Moreno,Gilberto
Rosales, Fernanda Vaz, Jordi Monés. Euretina Meeting. Barcelona,
May, 2002.
9.2.27. Photodynamic therapy in myopic CNV. Euretina Meeting.
Barcelona, May, 2002.
9.2.28. A New Automated Quantified Macular Metamorphopsia
Measurement in CNV treated with PDT. 25th ANNUAL MACULA
SOCIETY MEETING. Barcelona, June, 2002
9.2.29. Analysis of safety data of three randomized Trials of Verteporfin
therapy in the treatment of neovascular AMD XXIIIrd Congress of the
Club Jules Gonin in Montreux, Switzerland, 31 August - 4 Sep, 2002.
(PRESENTATIONS and LECTURES are presented together from this
point in the section 11.2)
10. TEACHING ACTIVITIES and INVITED LECTURES:
10.1. Organization of Scientific Courses:
10.1.1. Co-organization Curso " NUEVAS TÉCNICAS DE EXAMEN DEL
FONDO DE OJO: LA OFTALMOSCOPÍA CON LÁSER DE BARRIDO
(SLO)". Directores del Curso: Jordi Monés, Borja Corcóstegui. Centro
C. Vitae Jordi Monés 39
Retina Vitreo, Barcelona, October 23, 1993.
10.1.2. Fundator del “Club Angiográfico Fluoresceina – Indocianina,
Club FLIN”
10.1.3. Organization I Reunión Club Angiográfico FLIN. October 1995,
Barcelona.
10.1.4. Organization II Reunión Club Angiográfico FLIN. September
1996, Madrid.
10.1.5. Organization III Reunión Club Angiográfico FLIN. September
1997, Granada.
10.1.6. Co-organization Curso: Luxación posterior de núcleos
(Facoemulsificación ) y de LIO. Soluciones quirúrgicas. Implantes
secundarios. Directores: JR Soler Tomás, J Monés Carilla. LXXIII
CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA".
Granada, September 24-28, 1997.
10.1.7. Organization n IV Reunión Club Angiográfico FLIN. Alicante,
September 1988.
10.1.8. Co-organization I Reunión Grupo de Terapia Fotodinámica.
Venecia July 1999.
10.1.9. Organization V Reunión Club Angiográfico FLIN. Málaga,
September 1999.
10.1.10. Co-organization Curso Angiografía con Verde de Indocianina.
LXXV CONGRESO DE LA SOCIEDAD ESPAÑOLA DE
OFTALMOLOGÍA". Málaga, September 22, 1999.
10.1.11. Co-organization Curso Casos . LXXV CONGRESO DE LA
SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA". Málaga, September
22, 1999.
10.1.12. Co-organization II Reunión Grupo de Terapia
C. Vitae Jordi Monés 40
Fotodinámica.Deià, January, 2000.
10.1.13. Co-organization III Reunión Grupo de Terapia Fotodinámica.
Valladolid, June 2000.
10.1.14. Organization VI Reunión Club Angiográfico FLIN. Madrid
October 2000.
10.1.15. Chairperson Symposia: Visudyne: La Terapia Fotodinámica en
Oftalmología. 76 CONGRESO DE LA SOCIEDAD ESPAÑOLA DE
OFTALMOLOGÍA. Madrid, 11-15 October, 2000.
10.1.16. Coordinator: Round Table “Tratamiento con Láser, Terapeútica
Fotodinámica y Ayudas Visuales en DMAE. XI CONGRESO DE LA
SOCIEDAD ARAGONESA DE OFTALMOLOGÍA. Zaragoza, 10-11
November , 2000.
10.1.17. Organization and Coordination of an Interactive Course (700
people) “Alternativas Terapeúticas de la Neovascularización Coroidea:
Discusión de Casos Clínicos” V CONGRESO DE LA SOCIEDAD
ESPAÑOLA DE RETINA Y VITREO. Madrid, 2- 3 -March, 2001
10.1.18. Current Trials on Visudyne: 4th Int. Symp. on Ocular
Pharmacology and Pharmaceutics. Seville, March, 2002.
10.1.19. Course: Clinical Cases. II European Congress of PDT.
Barcelona, September, 2002.
10.1.20. Mesa redonda: "Avances en el tratamiento de la DMAE".
Moderador: Jordi Monés. Congreso Sociedad Española de Retina y
Vítreo. Santiago de Compostela, March, 2004.
10.1.21. Meeting New Horizons in AMD. Barcelona, March, 2005.
10.1.22. Ponencia Oficial 81 Congreso Sociedad Española de
Oftalmología, “La degeneración macular asociada a la edad”.
C. Vitae Jordi Monés 41
Zaragoza, Sept, 2005.
10.1.23. Actualización en DMAE. Directores: Jordi Monés i Carilla,
Francisco Gómez-Ulla de Irazazábal Nivel: Avanzado. 83 Congreso de
la Sociedad Española de Oftalmologia. Las Palmas de Gran Canaria,
Sept 26-29 , 2007.
10.1.24. Jordi Monés, Bayer Educational Slide Development/Speaker
Training. Vancouver, January 21-22, 2012.
10.2. Invited Lectures and invited participation in Courses:
10.2.1. Lecture: "Exploración Angiogràfica de la Coroides". I CURSO
DE PATOLOGÍA E INVESTIGACIÓN VÍTREAS. Valladolid, May 23-25,
1991.
10.2.2. Lecture: "Angiografía con indocianina verde mediante SLO en la
DMAE". CURS DE DOCTORAT 1993 - 94, UNIVERSITAT
AUTÒNOMA DE BARCELONA, HOSPITAL DE LA VALL D'HEBRON.
Barcelona, April 1993.
10.2.3. Discussion Poster Presentation: LXIX CONGRESO DE LA
SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Santiago de
Compostela, October 3, 1993.
10.2.4. Lecture: "AFG del Futuro". CURSO TEÓRICO-PRÁCTICO DE
LASERTERAPIA BÁSICA ARGON-YAG EN OFTALMOLOGÍA. Elx,
October 22, 1993.
10.2.5. Lecture: "Principios de la angiografía con indocianina verde".
Curso " NUEVAS TÉCNICAS DE EXAMEN DEL FONDO DE OJO: LA
OFTALMOSCOPÍA CON LÁSER DE BARRIDO (SLO)". Centro Retina
Vitreo. Barcelona, October 23, 1993.
10.2.6. Lecture: "Angiografía con indocianina verde mediante SLO en la
DMAE". Curso " NUEVAS TÉCNICAS DE EXAMEN DEL FONDO DE
C. Vitae Jordi Monés 42
OJO: LA OFTALMOSCOPÍA CON LÁSER DE BARRIDO (SLO)".
Centro Retina Vitreo. Barcelona, October 23, 1993.
10.2.7. Lecture: "Oftalmoscopia con Láser de Barrido (SLO)." "CURSO
DE ACTUALIZACIÓN EN OFTALMOLOGÍA", HOSPITAL PUERTA DE
HIERRO. Madrid, December 11, 1993.
10.2.8. Lecture: "Detección de neovasos subretinianos utilizando verde
de indocianina con el SLO". "CURSO DE AVANCES EN TÉCNICAS
QUIRÚRGICAS DE MICROCIRUGÍA OCULAR". Universitat
Autònoma de Barcelona. Barcelona, March 18, 1994.
10.2.9. Lecture: "Angiografía con indocianina verde - SLO en la
degeneración macular asociada a la edad". "SEMINARIO DEL MES
DE JUNIO" HOSPITAL UNIVERSITARIO, UNIVERSIDAD DE
VALLADOLID. Valladolid, June 25, 1994.
10.2.10. Round Table: "MESA REDONDA: Nuevos Métodos de
Exploración Retiniana". Participantes: Bertoja E, Marín F, Monés J,
Scheider A. Moderador: Gómez-Ulla F. LXX CONGRESO DE LA
SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Tenerife, September
30 - October 4, 1994.
10.2.11. Lecture: "Aplicaciones del Oftalmoscopio de Làser de Barrido
para las patologías de la Mácula". "JORNADAS CIENTÍFICAS 50
ANIVERSARIO DE LA FUNDACIÓN DE LA CLÍNICA QUIRÓN".
Barcelona, November 12, 1994.
10.2.12. Lecture: "Exploración de la circulación coroidea mediante
Videoangiografía con Verde de Indocianina - SLO" "CURSO DE
ANGIOGRAFÍA Y LÀSER EN PATOLOGÍA DE LA RETINA". Santiago
de Compostela, November 17-19, 1994.
10.2.13. Lecture: "Videoangiografía - SLO en las enfermedades
C. Vitae Jordi Monés 43
inflamatorias de la coroides y epitelio pigmentario". "CURSO DE
ANGIOGRAFÍA Y LÀSER EN PATOLOGÍA DE LA RETINA". Santiago
de Compostela, November 17-19, 1994
10.2.14. Lecture: "Clasificación de los patrones angiográficos con AVI -
SLO en las membranas neovasculares de la DMAE”. "CURSO DE
ANGIOGRAFÍA Y LÀSER EN PATOLOGÍA DE LA RETINA". Santiago
de Compostela, November 17-19, 1994.
10.2.15. Lecture: "Circulación coroidea de las formas exudativas de la
DMAE mediante VAGF-SLO." "CURSO DE ANGIOGRAFÍA Y LÀSER
EN PATOLOGÍA DE LA RETINA". Santiago de Compostela, November
17-19, 1994.
10.2.16. Lecture: "Oftalmoscopía làser de barrido (SLO) en el
diagnóstico y tratamiento de las patologías maculares". "SIMPOSIUM
MONOGRÁFICO SOBRE LA MÁCULA: NUEVAS TÉCNICAS
DIAGNÓSTICAS Y TERAPEÚTICAS". Valencia, January 14, 1995.
10.2.17. Round Table: "MESA REDONDA: Angiografía con verde de
Indocianina en la práctica oftalmológica". Participantes: Flower R,
Guyer D, Marín F, Monés J, Ruiz-Moreno JM. Moderador: Gómez-Ulla
F. " II CONGRESO DE LA SOCIEDAD ESPAÑOLA DE RETINA Y
VÍTREO". Madrid, February 24 - 25, 1995.
10.2.18. Lecture: " Angiografia amb indocianina verda: Avantatges i
aplicacions". "Departament d'Oftalmologia Clínica L'Aliança".
Barcelona, March 31, 1995.
10.2.19. Lecture: “Degeneració macular senil lligada a l’edat. Aspectes
clínics. Angiografies. SLO. “II JORNADA OFTALMOLOGICA DE
TARRAGONA: Lesions Maculars i Baixa visió”. Tortosa, May 4, 1996.
10.2.20. Lecture: "Utilidad del Scanning Laser Ophthalmoscope en el
diagnóstico diferencial de los tumores intraoculares". "CURSO DE
C. Vitae Jordi Monés 44
AVANCES EN EL TRATAMIENTO MÉDICO Y QUIRÚRGICO DE LOS
TUMORES INTRAOCULARES". Institut de Microcirurgia Ocular de
Barcelona. Barcelona, June 2-3, 1995.
10.2.21. Lecture: "Angiografía con indocianina verde. En: Uveitis:
Técnicas diagnósticas y de tratamiento". "IV CURSO DE
IMMUNOLOGIA OCULAR. MONOGRÁFICO: UVEITIS." IOBA,
Universidad de Valladolid. Sevilla, June 21-23, 1995.
10.2.22. Lecture: Scanning laser, angiografía con verde de indocianina y
microperimetría”. “TECNICAS DIAGNOSTICAS EN OFTALMOLOGIA”.
Pamplona, January 19-20, 1996.
10.2.23. Lecture: “Aplicaciones de la AVI en el diagnóstico y tratamiento
de las membranas neovasculares subretinianas” “FORMACION
MEDICA CONTINUADA DEL ILMO. COL. MEDICOS ALICANTE.
ACTUALIZACION EN ANGIOGRAFIA”. Alicante, February 3, 1996.
10.2.24. Course: “ Curso avanzado sobre angiografía con indocianina
verde” “1º CURSO DE LA SOCIEDAD ESPAÑOLA DE RETINA Y
VITREO”. Valladolid, February 24, 1996.
10.2.25. Round Table: “Retina Médica”. VII CONGRESO DE LA
SOCIEDAD ARAGONESA DE OFTALMOLOGIA. Zaragoza,
November 15-16, 1996.
10.2.26. Lecture: “Protocolo de la Terapia Fotodinámica” Mesa Redonda
MACULA. III CONGRESO DE LA SOCIEDAD ESPAÑOLA DE
RETINA Y VITREO. Madrid, February 21-22, 1997.
10.2.27. Lecture: “Verde de indocianina en las enfermedades
inflamatorias intraoculares”. “AVANCES EN EL DIAGNOSTICO Y
TRATAMIENTO DE LA INFLAMACION OCULAR”. Barcelona, May 23,
C. Vitae Jordi Monés 45
1997.
10.2.28. Round Table: “Degeneración macular asociada a la edad.
Terapia fotodinámica en las formas exudativas de la DMAE”. LXXIII
CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA.
Granada, September 24-28, 1997.
10.2.29. Discussion Poster Presentation LXXIII CONGRESO DE LA
SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Granada, September
25, 1997.
10.2.30. Course: “LIO en ausencia de cápsula” LXXIII CONGRESO DE
LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Granada,
September 25, 1997.
10.2.31. Course: La angiografía con indocianina en la préactica clínica.
LXXIII CONGRESO DE LA SOCIEDAD ESPAÑOLA DE
OFTALMOLOGÍA. Granada, September 25, 1997.
10.2.32. Lecture: “Hallazgos angiográficos mediante verde de indocianina
en las enfermedades inflamatorias coroideas”. CURSO “LA MÁCULA:
DIAGNÓSTICO Y TRATAMIENTO QUIRÚRGICO”. Hospital Clínic i
Universitari. Valencia, January 16-17, 1998.
10.2.33. Lecture: “Terapia fotodinámica mediante verteporfina para el
tratamiento de las formas exudativas subfoveales de la degeneración
macular asociada a la edad”. CURSO “LA MÁCULA: DIAGNÓSTICO
Y TRATAMIENTO QUIRÚRGICO”. Hospital Clínic i Universitari.
Valencia, January 16-17, 1998.
10.2.34. Lecture: “Terapia fotodinámica mediante verteporfina para el
tratammiento de las formas exudativas subfoveales de la degeneración
macular asociada a la edad”. SEMINARIO. DEPARTAMENTO DE
OFTALMOLOGIA, FACULTAD DE MEDICINA UNIVERSIDAD DE
VALLADOLID. Valladolid, January 24, 1998.
C. Vitae Jordi Monés 46
10.2.35. Clinical Cases: Presentación interactiva de casos clínicos: II
CURSO DE LA SOCIEDAD ESPAÑOLA DE RETINA Y VÍTREO.
Sevilla, February 28, 1998.
10.2.36. Lecture: “Terapia Fotodinámica en la Neovascularización
Coroidea”. CURSO DE POSTGRADO RETINA MÉDICA Y
QUIRÚRGICA. Casos Especiales. Institut Universitari Barraquer.
Barcelona, March 28, 1998.
10.2.37. Lecture: “Terapia Fotodinámica en la Neovascularización
Coroidea”. NUEVAS PERSPECTIVAS EN LA DEGENERACIÓN
MACULAR ASOCIADA A LA EDAD. Instituto Clínico Quirúrgico de
Oftalmología. Bilbao, April 25, 1998.
10.2.38. Round Table: “Estado Actual de la Patología Macular”. XXX
CONGRESO DE LA SOCIEDAD OFTALMOLÓGICA DE ANDALUCIA
Y EXTREMADURA. Marbella, June 26-28, 1998.
10.2.39. Course: “Alternativas terapeúticas de la DMAE”. 74
CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGIA.
Alicante, Sept 30 -October 4, 1998.
10.2.40. Course: “ Angiografía con verde de indocianina”. 74
CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGIA.
Alicante, Sept 30 - October 4, 1998.
10.2.41. Lecture: “Avances en el diagnóstico y tratamiento no quirúrgico
de las enfermedades de la mácula.” I CURSO DE ACTUALIZACIÓN
EN EL DIAGNOSTICO Y TRATAMIENTO DE LAS ENFERMEDADES
DE LA MACULA. Sociedad Canaria de Oftalmología. Las Palmas,
November 27-28, 1998.
10.2.42. Lecture: Terapia Fotodinámica: Nuevas Técnicas Quirúrgicas e
Instrumentos. IV CONGRESO DE LA SOCIEDAD ESPAÑOLA DE
RETINA Y VÍTREO. Madrid, February 19-20, 1999.
C. Vitae Jordi Monés 47
10.2.43. Lecture: “Nou tractament de la degeneració macular. Terapia
Fotodinámica” Hospital de la Creu Roja. Barcelona, March 10, 1999.
10.2.44. Lecture: Oclusiones coroideas asociadas al tratamiento de la
neovascularización subretiniana. III Curso Internacional de Retina
Médica y Diabetes Ocular. Santiago de Compostela, April 23-24, 1999.
10.2.45. Lecture: Terapia Fotodinámica en la DMAE. Resultados
preliminares. III Curso Internacional de Retina Médica y Diabetes
Ocular. Santiago de Compostela, April 23-24, 1999.
10.2.46. Training Course: Introducción a la Terapia Fotodinámica y
Resultados Ensayo Clínico Fase I y Fase III TFD. Curso – I Reunión
Grupo de Terapia Fotodinámica. Venecia, July 1999.
10.2.47. Training Course Descripción Ensayo Clínico Fase III TFD. Curso
– I Reunión Grupo de Terapia Fotodinámica. Venecia, July 1999.
10.2.48. Training Course Resultados Ensayo Clínico Fase III TFD. Curso
– I Reunión Grupo de Terapia Fotodinámica. Venecia, July 1999.
10.2.49. Training Course Presentación de casos clínicos. Revisión
criterios de inclusión TFD en uso compasivo. Curso- I Reunión Grupo
de Terapia Fotodinámica. Venecia, July, 1999.
10.2.50. Training Course: Fundamentals of Photdynamic Therapy (TFD).
Training course VIT (Verteporfin Italy Trial). Sardinia, September,
1999.
10.2.51. Training Course: Phase I-III of Photodynamic Therapy with
Verteporfin. Training course VIT (Verteporfin Italy Trial). Sardinia,
September, 1999.
10.2.52. Training Course: Case presentation. Phase I and phase II of
Photodynamic Therapy with Verteporfin. Training course VIT
(Verteporfin Italy Trial). Sardinia, September, 1999.
C. Vitae Jordi Monés 48
10.2.53. Course: Angiografía con Verde de Indocianina. LXXV
CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA".
Málaga, September 22, 1999.
10.2.54. Course: Casos clínicos . LXXV CONGRESO DE LA SOCIEDAD
ESPAÑOLA DE OFTALMOLOGÍA". Málaga, September 22, 1999.
10.2.55. Discussion Poster Presentation: LXXV CONGRESO DE LA
SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Málaga, September
24, 1999.
10.2.56. Round Table. Terapia Fotodinámica con Verteporfin.
Symposium Degeneración Macular Asociada a la Edad. LXXV
CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA.
Málaga, September 24, 1999.
10.2.57. Visudyne Therapy. CibaVision in-booth theather. American
Academy of Ophthalmology. Orlando, USA. October 25, 1999.
10.2.58. Round Table: Degeneració macular associada a l’edat:
possibilitats actuals de tractament. Terapia Fotodinámica. Aplicació
actual. 30 Congrés de la Societat Catalana d’Oftalmologia. Barcelona,
November 25-27, 1999.
10.2.59. Lecture: Terapia Fotodinámica con Verteporfin. XLII Congresso
de la Sociedade Portuguesa de Oftalmologia. Lisboa, December 1-4,
1999.
10.2.60. Lecture: Principles of Photodynamic Therapy. “Photodynamic
Therapy Leaders Symposium”. Vienna, December 11, 1999.
10.2.61. Lecture: Estado actual del uso compasivo de la Terapia
Fotodinámica para el tratamiento de la neovascularización coroidea
secundaria a DMAE. Mallorca, January, 2000
C. Vitae Jordi Monés 49
10.2.62. Lecture: Ull vermell i Glaucoma. XII Curs de Formació
Continuada. Actualitzacions diagnòstiques i Terapeútiques. Hospital
de Mataró . Barcelona, February 24, 2000.
10.2.63. Lecture: Estat actual de la Terapia Fotodinámica en
Degeneració Macular Asociada a la Edad. XII Curs de Formació
Continuada. Actualitzacions diagnòstiques i Terapeútiques. Hospital
de Mataró. Barcelona, February 24, 2000
10.2.64. Course: DECISIONES TERAPEÚTICAS siguiendo CRITERIOS
ANGIOGRÁFICOS. Curso Angiografía y su Implicación Terapeútica en
DMAE. Curso de la Sociedad Española de Retina Vítreo. Bilbao,
February 26, 2000.
10.2.65. Lecture: Estado actual Terapia Fotodinámica. Sesión
Degeneración Macular Asociada a la Edad. Curso de la Sociedad
Española de Retina Vítreo. Bilbao, February 26, 2000.
10.2.66. Lecture: One-year results of TAP Study of Photodynamic
Therapy with Verteporfin. Vitreoretinal Interface Course. Rome, March
31, 2000.
10.2.67. Lecture: Estado Actual de la Terapia Fotodinámica. Symposium
de Terapia Fotodinámica con Verteporfin. Buenos Aires, Argentina.
May 11, 2000.
10.2.68. Lecture: Estado Actual de la Terapia Fotodinámica. Curso de
Perfeccionamiento para Oftalmólogos. Sociedad Chilena de
Oftalmología. Santiago de Chile, Chile. May 12, 2000.
10.2.69. Lecture: Decisiones Terapeúticas siguiendo criterios
angiográficos en DMAE. Curso de Perfeccionamiento para
Oftalmólogos. Sociedad Chilena de Oftalmología. Santiago de Chile,
Chile. May 12, 2000.
C. Vitae Jordi Monés 50
10.2.70. Breakfast with Experts: Terapia Fotodinámica. Curso de
Perfeccionamiento para Oftalmólogos. Sociedad Chilena de
Oftalmología. Santiago de Chile, Chile. May 12, 2000.
10.2.71. Resultados Uso Compasivo Terapia Fotodinámica en DMAE.
Curso Nuevos Avances en el Diagnóstico y Tratamiento quirúrgico en
Oftalmología. Servicio Oftalmología Hospital Vall d’Hebrón. Barcelona,
May 19- 20, 2000.
10.2.72. Lecture: Protoporfirinas en la DMAE. Actualización en
Degeneraciones y Distrofias Retinianas. IOBA. Valladolid, June-3,
2000.
10.2.73. Lecture: Terapia Fotodinámica en miopía. Miopía 2000.
Asociación Oftalmológica del Norte. Vitoria, Spain. June 9, 2000.
10.2.74. Lecture: Fundamentals of Photodynamic Therapy. Creteil
Course on PDT. Cannes, France. June 10, 2000.
10.2.75. Lecture: Photodynamic Therapy in Myopia: VIP Trial. UK
Visudyne Symposium. Geneve, September 30, 2000.
10.2.76. Compassionate use in Barcelona of Photodymanic Therapy: 1
year results. UK Visudyne Symposium. Geneve, September 30, 2000.
10.2.77. TAP Study. 2-year angiographic results. Symposia: Visudyne:
La Terapia Fotodinámica en Oftalmología. 76 CONGRESO DE LA
SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Madrid, 11-15 October,
2000.
10.2.78. Terapia Fotodinámica: 1 año de resultados en Fase de Uso
Compasivo en Barcelona. Symposium Visudyne: La Terapia
Fotodinámica en Oftalmología. 76 CONGRESO DE LA SOCIEDAD
ESPAÑOLA DE OFTALMOLOGÍA. Madrid, October 14, 2000.
10.2.79. Decisiones Terapeúticas para la DMAE sobre criterios
angiográficos. Symposium en Degneración Macular Asociada a la
C. Vitae Jordi Monés 51
Edad. 76 CONGRESO DE LA SOCIEDAD ESPAÑOLA DE
OFTALMOLOGÍA. Madrid, October 15, 2000.
10.2.80. Desayuno con expertos. Degeneración Macular Asociada a la
edad. 76 CONGRESO DE LA SOCIEDAD ESPAÑOLA DE
OFTALMOLOGÍA. Madrid, October 14, 2000.
10.2.81. Terapia Fotodinámica Estudio TAP: Resultados 2 años.
Reunión Satélite AMERICAN ACADEMY OF OPHTHALMOLOGY
MEETING 2000, Symposium Visudyne Iberoamérica. Dallas, October
23, 2000.
10.2.82. Instructor Skill transfer Program: Photodynamic Therapy:
Current treatment guidelines for choroidal neovascularization. Course
HO-601. AMERICAN ACADEMY OF OPHTHALMOLOGY MEETING.
Dallas, October 25, 2000.
10.2.83. Terapéutica Fotodinámica. Experiencia personal y Estudio
multicéntrico. XI CONGRESO DE LA SOCIEDAD ARAGONESA DE
OFTALMOLOGÍA. Zaragoza, November 10-11, 2000.
10.2.84. Mesa Redonda “Terapéuticas Acctuales en la Degeneración de
Mácula asociadas a la Edad” REUNION ANUAL DE LA ASOCIACIÓN
OFTALMOLÓGICA DEL NORTE. Bilbao, November 18, 2000.
10.2.85. Terapia Fotodinàmica amb Verteporfino en DMAE. Estudi TAP:
Resultats de 2 anys. Satellite Symposium 31 CONGRÉS DE LA
SOCIETAT CATALANA D’OFTALMOLOGIA”. Barcelona, November
23-24, 2000.
10.2.86. Experiencia en Terapia Fotodinámica en Oftalmología. X
CONGRESO DE LASER EN MEDICINA Y CIRUGÍA. México DF,
C. Vitae Jordi Monés 52
México. November 28 , 2000.
10.2.87. Estado Actual de Ensayos Clínicos en la Neovascularización
Coroidea SESION CLÍNICA INSTITUT MICROCIRURGIA OCULAR
DE BARCELONA. Barcelona, February, 2001.
10.2.88. Estado Actual de Ensayos Clínicos en la Neovascularización
Coroidea. V CONGRESO DE LA SOCIEDAD ESPAÑOLA DE RETINA
Y VITREO. Madrid, March 2- 3, 2001
10.2.89. Lecture: The TAP Study. NEW ASPECTS IN THE
TREATMENT OF AGE-RELATED MACULAR DEGENERATION.
Rome, March 10, 2001.
10.2.90. Terapia Fotodinámica en Miopía y Degeneración Macular
Asociada a la Edad ( Estudio VIP, resultados a 24 meses ). III CURSO
INTERNACIONAL “LO ACTUALMENTE POSIBLE EN
ENFERMEDADES VITREORRETINIANAS” México DF, México. 22-24
de Marzo 2001.
10.2.91. Ensayo Clínico de la Degeneración Macular Asociada a la Edad
(Estudio TAP) Resultados a 36 meses ). III CURSO INTERNACIONAL
“LO ACTUALMENTE POSIBLE EN ENFERMEDADES
VITREORRETINIANAS” México DF, México. March 22-24, 2001.
10.2.92. Management of Visudyne Therapy: Treatment and follow-up
procedures. Course Visudyne therapy for Neovascular Disorders of the
Macula – Introduction to Visudyne Therapy. XIII Congress of The
European Society of Ophthalmology. Istanbul, June -7, 2001.
10.2.93. Visudyne Therapy in Pathologic Myopia: 24-month Update from
VIP Study. Symposia Visudyne in Clinical Practice: Trial Updates and
Recommended Patient Management. XIII Congress of The European
C. Vitae Jordi Monés 53
Society of Ophthalmology. Istanbul, June -7, 2001.
10.2.94. Control del Paciente. Indicación de los retratamientos.
Simposium sobre Fototerapia Dinámica. GLADAOF Meeting. Buenos
Aires, July 21, 2001.
10.2.95. Paper: Visudyne Therapy in Patients with AMD: Experience from
Trials and Clinical Practice. 77 CONGRESO DE LA SOCIEDAD
ESPAÑOLA DE OFTALMOLOGÍA. Barcelona, October, 2001.
10.2.96. Lecture: Current and Future Treatments in AMD. Challenges In
PDT For Choroidal Neovascularisation, Liverpool Medical Institution.
Liverpool, October 16, 2001.
10.2.97. Lecture: Terapia Fotodinàmica en DMAE: Patología de la
Mácula, Alicante, October 19,2001..
10.2.98. Lecture: Current and Future Treatments in AMD. Curso
Actualizaçáo Oftalmológica. Lisboa, October 27, 2001.
10.2.99. Clinical Session.Casos Clínicos: Retratamientos TFD en NVC –
Miopía.Monitorización Metamorfopsia. I.M.O. Barcelona, January 29,
2002
10.2.100. Polypoidal Choroidal Vasculopathy in recurrent CNV after PDT
Clinical Session. Reunió Hivern Retina de Barcelona. Baqueira,
February, 2002.
10.2.101. Anti-VEGF in exudative AMD 4th Int. Symp. On Ocular
Pharmacology and Pharmaceutics. Seville, March, 2002.
10.2.102. Decision making in PDT retreatments. Monitoring
metamorphopsia. 4th Int. Symp. On Ocular Pharmacology and
Pharmaceutics,Seville, March 2002
10.2.103. Current trials on Visudyne. 4th Int. Symp. On Ocular
Pharmacology and Pharmaceutics. Seville, March, 2002.
C. Vitae Jordi Monés 54
10.2.104. Discussion Paper: Lluis Arias, TFD en C.S.U. Bellvitge:
Resultados en DMAE y MP. VI CONGRESO DE LA SOCIEDAD
ESPAÑOLA DE RETINA Y VITREO. San Sebastián, March, 2002.
10.2.105. Current and FutureTreatments in AMD. Padova, April 4, 2002.
10.2.106. Principles of Photodynamic Therapy. TÜRK OFTALMOLOJI
DERNEGI. Ankara, April, 2002.
10.2.107. Visudyne Therapy in Patients with AMD:Experience from Trials
and Clinical Practice. TÜRK OFTALMOLOJI DERNEGI. Ankara, April,
2002.
10.2.108. Photodynamic Therapy with Verteporfin in AMD. Experience
from Trials and Clinical Practice. TÜRK OFTALMOLOJI DERNEGI.
Ankara, April, 2002.
10.2.109. Treatment Response — Beyond Visual Acuity. International
Congress in Opthalmlogy. Sidney, Australia. April, 2002.
10.2.110. Terapia Fotodinámica. Retratamientos. Actualización en el
diagnóstico y tratamientos de complejos neovasculares subretinianos.
Madrid, May 11, 2002.
10.2.111. Visudyne Therapy in Patients with AMD:Experience from Trials
and Clinical Practice. Actualización en el diagnóstico y tratamientos de
complejos neovasculares subretinianos. Madrid, May 11, 2002.
10.2.112. Current Trials on Visudyne: Rationale for VER and VIM Study.
Actualización en el diagnóstico y tratamientos de complejos
neovasculares subretinianos. Madrid, May 11, 2002.
10.2.113. Practical algorithms on PDT retreatment in AMD and myopia.
G.I.V.R.E. Course. Parma, May, 2002.
10.2.114. Course: Clinical Cases. II European Congress of PDT.
C. Vitae Jordi Monés 55
Barcelona, September, 2002.
10.2.115. Clinical Session: Tratamientos vasos nutricios en
Neovascularización coroidea. I.M.O. Barcelona, December 10, 2002.
10.2.116. Tratamiento de la neovascularización coroidea: Actividad de alto
riesgo? Curso Actualización DMAE. Sevilla, January 25, 2003.
10.2.117. Tratamiento de la neovascularización coroidea: Actividad de alto
riesgo? VII CONGRESO DE LA SOCIEDAD ESPAÑOLA DE RETINA Y
VITREO. Madrid, February 27, 2003.
10.2.118. Clinical Session: The Anecortave Acetate for Exudative AMD:
Clinical Outcomes and Status of Clinical Studies. I.M.O. Barcelona,
May, 2003.
10.2.119. Lecture: The Anecortave Acetate for Exudative AMD: Clinical
Outcomes and Status of Clinical Studies. 14th Congress of The
European Society of Ophthalmology. Madrid, June, 2003
10.2.120. Lecture: Is Lesion Size as Important as Lesion Composition?
14th Congress of The European Society of Ophthalmology. Madrid,
June 2003
10.2.121. Lecture: The Anecortave Acetate for Exudative AMD: Clinical
Outcomes and Status of Clinical Studies. Firenze, September 4, 2003.
10.2.122. Lecture: Preferential Hyperacuity Perimetry (PHP): A new way
for monitoring CNV progression. VI INTERNATIONAL
CONGRESS:Myopia and Related Diseases: A clinical and therapeutic
approach. Rome. September, 2003
10.2.123. Lecture: Implications of contrast sensitivity preservation in AMD
patients treated with Visudyne therapy. III European Congress on PDT
in AMD Management. Cannes, October 3-4, 2003.
C. Vitae Jordi Monés 56
10.2.124. PDT using delayed light application in occult lesions: Results
from VALIO. III European Congress on PDT in AMD Management.
Cannes, October 3-4, 2003.
10.2.125. Clinical Session: Translocación Macular asociado a Terapia
Fotodinámica en NVC 2ria a Miopia Patológica. I.M.O. Barcelona,
October 14, 2003.
10.2.126. Course: Translocación Macular asociado a Terapia
Fotodinámica en NVC 2ria a Miopia Patológica. 79 CONGRESO DE LA
SOCIEDAD ESPAÑOLA DE OFTALMOLCGÍA. Valencia, October
2003.
10.2.127. Lecture: Is Lesion Size as Important as Lesion Composition? V
Reunión Club Visudyne. Las Vegas USA, November, 2003.
10.2.128. Management of AMD, Training course for the Alcon company
executives. Barcelona, December, 2003
10.2.129. Current management in AMD, QLTI Analyst and Investor
Meeting. New York, December, 2003.
10.2.130. Tratamiento NVC en la Retinopatía Diabética. Curso
Oftalmodiabetes, Hospital de l’Esperança. Barcelona, February, 2004
10.2.131. Preferential Hyperacuity Perimetry (PHP) for monitoring myopic
CNV treated with PDT. 2004 Annual Meeting Macula Society. Las
Vegas, 2004.
10.2.132. Mesa redonda: "Avances en el tratamiento de la DMAE
".Moderador: Jordi Monés. Congreso Sociedad Española de Retina y
Vítreo. Santiago de Compostela, March, 2004.
C. Vitae Jordi Monés 57
10.2.133. Terapia Fotodinámica y Corticoides. Congreso Sociedad
Española de Retina y Vítreo. Santiago de Compostela, March, 2004.
10.2.134. Tratamiento antiangiogénico en DMAE. Congreso Sociedad
Española de Retina y Vítreo. Santiago de Compostela, March, 2004.
10.2.135. PDT New drugs. Panel discussion. ISOPT Meeting, Montecarlo,
March, 2004.
10.2.136. Refining Management of CNV due to AMD − Maximising Patient
Benefit through Prompt and Appropriate Treatment. ISOPT Meeting,
Montecarlo, March, 2004.
10.2.137. Tratamiento combinado:TFD + triamcinolona IVIT en NVC.
Sesión Clínica IMO, Barcelona, March, 2004.
10.2.138. Curso Angiográfico Hospital de Sant Pau. Barcelona, April, 2004
10.2.139. Terapia Antiangiogénica. Curso Macula. Institut Oftalmologia
Barraquer, June, 2004.
10.2.140. Terapia Antiangiogénica. Curso Instituto Fernández-Vega.
Oviedo, June 2004.
10.2.141. Terapia combinada, PDT y triamcinolona. Reunión de trabajo
Club Visudyne. Sitges, September 2004.
10.2.142. Chair: Jordi M. Mones, MD,Section II: Photodynamic Therapy
and Corticosteroids for AMD. Subspecialty day Retina, Annual Meeting
C. Vitae Jordi Monés 58
of the American Academy of Ophthalmology. New Orleans, USA.
October 2004.
10.2.143. Pfizer Macugen Worldwide Advisory Board. New Orleans, USA.
October 2004.
10.2.144. Preferential Hyperacuity Perimetry for monitoring CNV. Couse
(E. Midena) at the Annual Meeting of the American Academy of
Ophthalmology. New Orleans, USA October 2004.
10.2.145. Efficacy of Macugen. Reunión Mexican Advisory Board.
Cuernavaca, México. October, 2004.
10.2.146. Safety of Macugen. Efficacy of Macugen. Reunión Mexican
Advisory Board. Cuernavaca, México. October, 2004.
10.2.147. Meeting of the European Group for the guidelines of treatment of
AMD. Paris, November, 2004.
10.2.148. Clinical cases presentation. Soc. Lombarda oftalmologia. Milan
December, 2005.
10.2.149. Curso Formación Degeneración Macular asociada a a la edad,
Pfizer. Madrid, December, 2004
10.2.150. Sesión clínica IMO. Fármacos intravítreos. IMO. Barcelona,
January, 2005.
10.2.151. Casos clínicos. Andorra, February 2005.
C. Vitae Jordi Monés 59
10.2.152. Tratamiento Combinado en NVC: Terapia Fotodinámica y
Triamcinolona transeptal. Reunión Sociedad Española de Retina y
Vítreo, Madrid, February, 2005.
10.2.153. Curso satélite para oftalmólogos “Perimetría de Hiperagudeza
Preferencial”. Reunión Sociedad Española de Retina y Vítreo. Madrid,
February, 2005.
10.2.154. Curso satélite para ópticos y periodistas. “Perimetría de
Hiperagudeza Preferencial”. Reunión Sociedad Española de Retina y
Vítreo. Madrid February, 2005.
10.2.155. Clinical case presentation session. Meeting New Horizons in
AMD. Barcelona, March, 2005.
10.2.156. Anti-VEGF therapy: clinical efficacy and safety of Macugen
New Horizons in AMD. Barcelona, March, 2005.
10.2.157. Esquema diagnóstico y tratamiento en DMAE. Reunión
Panamerican Academy of Ophthalmology. Santiago de Chile, March,
2005.
10.2.158. Update in Macugen, Reunión Panamerican Academy of
Ophthalmology. Santiago de Chile, March, 2005.
10.2.159. Macugen therapy. Sessió clínica Hospital de la Vall d’Hebró.
April 2005
10.2.160. Update in Macugen. Euretina Meeting. Barcelona, May, 2005.
C. Vitae Jordi Monés 60
10.2.161. Limitations of intravitreal triamcinole as adjuntive therapy with
PDT. Meeting “Retina in Progress” Prof. A Pecce. Milan, Italy, June,
2005.
10.2.162. Terapia antiangiogénica. Sesión clínica Hospital de l’Esperança.
Barcelona, June, 2005.
10.2.163. Limitaciones de la triamcinolona intravítrea. Curso de la APEC,
Ciudad de México. México, September 2005.
10.2.164. Perimetría de hiperagudeza preferencial. Curso de la APEC,
Ciudad de México. México, September, 2005
10.2.165. Esquema diagnóstico y terapeútico de la DMAE. Curso de la
APEC, Ciudad de México. México, September, 2005.
10.2.166. Tratamiento con pegaptanib sódico, Macugen, en DMAE. Curso
de la APEC, Ciudad de México. México, September, 2005.
10.2.167. Main Lecture of the 81 Meeting of the Spanish Society of
Ophthalmology: Degeneración Macular Asociada a la Edad”. 81 reunión
de la Soc. Esp. Oftalmología. Zaragoza, September, 2005.
10.2.168. Lo mejor de la reunión de ARVO, 81 reunión de la Soc. Esp.
Oftalmología, Zaragoza, September, 2005
10.2.169. Update in Macugen. 81 reunión de la Soc. Esp. Oftalmología.
Zaragoza, September, 2005.
10.2.170. Macugen and Neovascular AMD. VISION Trials. 2 year data.
EVER 2005. European Association for Vision and Eye Research.
C. Vitae Jordi Monés 61
Vilamoura, Portugal October 5-8, 2005.
10.2.171. Que cal retenir dels Assaigs Clínics de DMAE. Societat Catalana
d’Oftalmologia. Catalunya, November 24-25, 2005
10.2.172. Macugen for CNV/ AMD. Ocular Pharmacology and
Therapeutics (ISOPT). Berlin, March 30-April 2, 2006.
10.2.173. Macugen for DME Ocular Pharmacology and Therapeutics
(ISOPT). Berlin, March 30-April 2, 2006.
10.2.174. Co-chair session Macular edema. Ocular Pharmacology and
Therapeutics (ISOPT). Berlin, March 30-April 2, 2006.
10.2.175. Macugen World Wide Advisory Board Meeting. Fort Lauderdale,
May 5-6, 2006.
10.2.176. J. Mones, J. Lotery, J. Pauleikhoff, G. Soubrane, A. Cruess, G.
Zlateva. Humanistic burden and health resource utilitsation among
neovascular age-related macular degeneration (AMD) patients: Results
from a multi-country cross-sectional study Euretina Congress. Lisbon,
May 18-21, 2006.
10.2.177. D. Pauleikhoff, J. Lotery, J. Mones, G. Soubrane, A. Cruess, G.
Zlateva, GERMANY. Impact of neovascular age-related macular
degeneration on medical status, daily living and health resource
utilisation: A survey of five countries Euretina Congress. Lisbon May
18-21, 2006.
10.2.178. Chair Session Free Papers New Therapies on AMD. Euretina
Congress. Lisbon May 18-21, 2006.
C. Vitae Jordi Monés 62
10.2.179. J. Mones, Two-year efficacy results from MARINA, a
randomized, controlled, Phase III study of ranibizumab for minimally
classic or occult choroidal neovascularization secondary to AMD
Euretina Congress. Lisbon May 18-21, 2006.
10.2.180. Curso de Avances e Innovaciones en Oftalmología.
Ranibizumab y Bevacizumab en el tratamiento de la DMAE exudativa.
Barcelona, June 1-2, 2006.
10.2.181. Tratamiento de la DMAE exudativa mediante Bevacizumab.
Resultados a 6 meses. Comunicación libre. Congreso de la Sociedad
Española de Oftalmología A Coruña, Septiembre 27-30, 2006.
10.2.182. Resultados del Ensayo Marina a 2 años de Ranibizumab
(Lucentis®) intravítreo para el tratamiento de las lesiones ocultas y
mínimamente clásicas secundarias a DMAE exudativa. Congreso de la
Sociedad Española de Oftalmología A Coruña, September 27-30,
2006.
10.2.183. Resultados del Ensayo Anchor a un año comparando la eficacia
del tratamiento de la DMAE exudativa con Ranibizumab (Lucentis®) y
de la Terapia Fotodinámica. Comunicación de Investigación. Congreso
de la Sociedad Española de Oftalmología A Coruña, September 27-
302006
10.2.184. Hallazgos de Marina y Anchor: Tratamiento de membranas
ocultas y clásicas subfoveales Dr. Jordi Mones Carilla. Symposium
ANTIANGIOGÉNICOS: LLEGA LA NUEVA ERA 82 Congreso de la
Sociedad Española de Oftalmología A Coruña, September 27-30, 2006
C. Vitae Jordi Monés 63
10.2.185. Directores Curso: Francisco Gómez-Ulla, Jordi Mones. TERAPIA
ANTIANGIOGÉNICA EN PATOLOGÍA DE LA RETINA Colaboradores:
José M. Ruiz Moreno, Luis Arias, Máximo Abraldes, Maribel Fernández,
Joaquín Marticorena. Congreso de la Sociedad Española de
Oftalmología A Coruña, September 27-30,2006
10.2.186. Bevacizumab en DMAE exudativa. Curso AVANCES EN EL
TRATAMIENTO MEDICO QUIRURGICO DE LA PATALOGIA
MACULAR. Congreso de la Sociedad Española de Oftalmología A
Coruña, September 27-30, 2006
10.2.187. Quantification of improvements in visual acuity following
treatment with intravitreal ranibizumab in patients with CNV secondary
to AMD in the Anchor and Marina Trials. Retina Society – Club Jules
Gonin Meeting. Cape Town, South Africa. October 16-20, 2006.
10.2.188. Tratamiento de la DMAE exudativa mediante Bevacizumab.
Resultados a 6 meses. Curso DMAE; Hospital Germans Trias i Pujol.
Catalunya, November 3, 2006.
10.2.189. Management of AMD. Breakfast for Experts. American Academy
of Ophthalmology and Macula Society. American Academy of
Ophthalmology Meeting. Las Vegas, November 13, 2006.
10.2.190. Vision improvement as the new “gold standard” of care in AMD.
Looking forward in AMD > A new era in AMD treatment. Rome, March,
2007.
10.2.191. Advisory Board Allergan. Rome, March, 2007.
10.2.192. ¿Es avastin el hermano pobre de lucentis? I Simposium sobre
C. Vitae Jordi Monés 64
Controversias en Oftalmología. Hospital de Bellvitge. Barcelona, March,
2007.
10.2.193. Update lucentis. New Therapies for AMD. 7th Euretina
Congress. Montecarlo, May, 2007.
10.2.194. Against PDT still has a major role in the treatment of ARMD.
Amsterdam Retinal Debate. 7th Euretina Congress. Montecarlo, May,
2007.
10.2.195. Quantification of VA improvements Over Two Years in the
MARINA and ANCHOR Studies of Intravitreal Ranibizumab. Free
papers. 7th Euretina Congress. Montecarlo May 2007
10.2.196. Antiangiogénicos. II Curso de Actualización de Retina y Vitreo.
Oviedo, May, 2007.
10.2.197. La mejoría de la visión debe ser el nuevo estándar terapéutico
en la DMAE. Curso Actualización DMAE. Sitges, May, 2007.
10.2.198. Quantification of VA improvements Over Two Years in the
MARINA and ANCHOR Studies of Intravitreal Ranibizumab 0,3mg 0,5
mg for CNV secondary to AMD. Free papers. The Macula Society.
London June, 2007.
10.2.199. Mystery Case. Fluorescein cases for 2007.The Macula Society.
London, June, 2007
10.2.200. Actualización en DMAE Directores: Jordi Monés i Carilla,
Francisco Gómez-Ulla de Irazazábal Nivel: Avanzado. 83 Congreso de
la Sociedad Española de Oftalmologia. Las Palmas de Gran Canaria,
C. Vitae Jordi Monés 65
September 26-29 , 2007.
10.2.201. Simposium UNA NUEVA VISIÓN DE LA DMAE. Dr. Jordi
Monés: Eficacia. 83 Congreso de la Sociedad Española de
Oftalmologia, Las Palmas de Gran Canaria, September 26-29, 2007.
10.2.202. Ranibizumab for myopic choroidal neovascularization. The 7th
International Symposium on Ocular Pharmacology & Therapeutics.
February 28 -March 3, 2008.
10.2.203. Avastin for proliferative Diabetic Retinopathy. The 7th
International Symposium on Ocular Pharmacology & Therapeutics.
February 28- March 3, 2008.
10.2.204. Comunicación invitada: Aplicaciones Clínicas OCT Fourier
Domain. XII Congreso de la Sociedad Española de Retina y Vítreo.
Zaragoza, March 8, 2008.
10.2.205. Conferencia invitada: Aplicaciones Clínicas OCT Fourier
Domain. Reunió International Meeting Topcon. Sevilla, March 14,
2008.
10.2.206. Efectos adversos anti VEGF BARRAQUER, Curso Instituto
Barraquer, Barcelona, April 2008
10.2.207. La Ceguera Evitable, DMAE y Retinopatia diabética.b
Cuadernos Diálogos para la Salud, Centro Médico Teknon. April 18,
2008
10.2.208. Pro Neuroprotection. Implications of curretn treaments. Allergan
advisory board. Annual Meeting Association for Reasearch in vision and
C. Vitae Jordi Monés 66
ophthalmology. Fort Lauderdale, USA. May 1-5, 2008
10.2.209. Tractament actual de la degeneració macular associada a l’edat.
Conferencia Escola Optica Girona. Girona, May 8, 2008
10.2.210. Tractament actual de la degeneració macular associada a l’edat.
Col·legi d’òptics de Lleida. Lleida, May 22, 2008
10.2.211. Ranibizumab en neovascularización coroidea BARRAQUER
Curs Barraquer. Barcelona, May 16, 2008
10.2.212. Avastin in Proliferative Diabetic Retinopathy. Primer Encuentro
de Retina Quirúrgica. Menorca, June 13-14, 2008.
10.2.213. Tractament actual de la degeneració macular associada a l’edat.
Conferència Col.legi d’Òptics, Tarragona, July 16, 2008
10.2.214. Ranibizumab en DMAE en regimen a demanda. 84 Congreso de
la Sociedad Española de Oftalmología. Sevilla, September 26, 2008
10.2.215. Ranibizumab en MIOPIA. 84 Congreso de la Sociedad Española
de Oftalmología. Sevilla, September 26, 200
10.2.216. DMAE i NVC. Clinica Juaneda. Palma de Mallorca, October
2008.
10.2.217. Ceguesa Evitable. Càtedra Unesco. Dia internacional de la visió.
Escola d’Óptica de Terrassa. Terrassa, October 9, 2008.
10.2.218. Searching for the optimal dosing. Current update (AMD). 8th
C. Vitae Jordi Monés 67
International AMD Congress. Firenze, October 17-18, 2008.
10.2.219. Safety and tolerability of two dosing regimens of ranibizumab in
patients with subfoveal choroidal neovascularisation secondary to age-
related macular degeneration: EXCITE secondary outcomes. XXVIth
Meeting Club Jules Gonin. St. Moritz, Switzerland. September 11-14,
2008.
10.2.220. Member of Scientific Advisory Board. The 7th International
Symposium on Ocular Pharmacology & Therapeutics. February 28-
March3, 2008.
10.2.221. Jordi Monés Conferència magistral, The Friedman’s lecture: “
AMD: From desperation to Hope. Massachusetts Eye and Ear Infirmary,
Harvard Medical School. Boston, Massachusetts, USA Febrer 18, 2009.
10.2.222. Jordi Monés: DMAE y RANIBIZUMAB Congreso bienal
deEgresadoOftalmología centro medico nacional de occidente.
Guadalajara, Mexico. March 5, 2009.
10.2.223. Jordi Monés: DMAE y TERAPIA ANTI PDGF Congreso bienal
de EgresadoOftalmología centro medico nacional de occidente.
Guadalajara, Mexico. March 5, 2009.
10.2.224. Jordi Monés: DMAE y TERAPIA MONOCLONAL ANTI UNION
DE INTEGRINAS -‘FIBRONECTINA Congreso bienal de Egresado
Oftalmología centro medico nacional de occidente. Guadalajara,
Mexico. March 5 , 2009.
10.2.225. Jordi Monés, Lluis Arias Vitrectomía transconjuntival
microincisional + rtPA + SF6 + Avastin. Congreso bienal de Egresado
C. Vitae Jordi Monés 68
Oftalmología centro medico nacional de occidente. Guadalajara,
Mexico. March 5, 2009.
10.2.226. Jordi Monés. ‘Current status of the examination and treatment of
diabetic retinopathy’ L’Institute Cardiovasculare de Paris, Centro
Médico Teknon. Barcelona, March 13, 2009.
10.2.227. Jordi Monés, Lluis Arias: Terapia anti PDGF combinada con anti
VEGF en DMAE exudativa. Congreso Sociedad Española de Retina
Vitreo. Madrid March, 2009.
10.2.228. Jordi Monés: Esport i Trauma Ocular. Acadeèmia de Ciències
Mèdiques de Catalunya i Balears, Centre d’Alt Rendiment de Sant
Cugat. Barcelona, March 27, 2009.
10.2.229. Jordi Monés, Samir Patel: Blocking Complement Factor 5 in
neovascular AMD: Phase I Study. 9th Euretina Congress. Nice, France.
May 14-17, 2009.
10.2.230. Jordi Monés: AMD Course, Dr Sobrane: Translating clinical
evidence into treatment guidelines: In the search of the optimal dosing.
9th Euretina Congress, Nice, France 14-17 may, 2009.
10.2.231. Jordi Monés for the Ophthotech Anti-α5β1 Integrin in AMD Study
Group Interference of Cell Survival Signals by Targeting α5β1 Integrin
(with Volociximab) and Vascular Endothelial Growth Factor in Subjects
with Neovascular Age-related Macular Degeneration (AMD) – Results
of a Phase 1 Study. SOE 2009, The 17th Congress of the European
Society of ophthalmology, 13-16 june 2009
10.2.232. Jordi Monés at the Reonet Novartis Advisory The 17th Congress
C. Vitae Jordi Monés 69
of the European Society of ophthalmology, 13-16 june 2009
10.2.233. Jordi Monés at Eyesense Scientific Advisory Board. September
15th, Barcelona
10.2.234. Jordi Monés, Nueva evidencia de ranibizumab en DMAE
neovascular: Estudios SUSTAIN y EXCITE.SEO Sociedad Española
de Oftalmologia, 24-25 september 2009, Santander.
10.2.235. Jordi Monés, Lluis Arias, Marc Biarnés: Symposium Angelini.
DMAE seca: El nuevo reto. Sociedad Española de Oftalmologia, 24-25
september 2009, Santander
10.2.236. Jordi Monés: Symposium OCT Spectralis: Avances en Técnicas
diagnósticas para la DMAE seca. Sociedad Española de Oftalmologia,
24-25 september 2009, Santander.
10.2.237. Jordi Monés: Combined Inhibition of a5B1 Integrin and Vascular
Endothelial Growth Factor for Neovascular Age-Related Macular
Degeneration – Phase 1 Study Retina Congress 2009 New York,
september 29-0ct 4
10.2.238. Jordi Monés at the ERAB Allergan Advisory Board Meeting. Sept
29, New York
10.2.239. Jordi Monés: Potential Future Treatments for Neovascular AMD.
2009 International AMD and Retina Congress: Focusing of the issues of
Today and looking to the future. 9-10 Oct, 2009.
10.2.240. Jordi Monés at Meet with the Experts: safety of anti VEGF
treatments. 2009 International AMD and Retina Congress: Focusing of
C. Vitae Jordi Monés 70
the issues of Today and looking to the future. 9-10 Oct, 2009.
10.2.241. Jordi Monés at Meet with the Experts: Daibetic Macular Edema
and Retinal Vein Occlusion. 2009 International AMD and Retina
Congress: Focusing of the issues of Today and looking to the future. 9-
10 Oct, 2009.
10.2.242. Jordi Monés at the Scientific Committee 2009 International AMD
and Retina Congress: Focusing of the issues of Today and looking to
the future. 9-10 Oct, 2009.
10.2.243. Jordi Monés “Phase III Study of Dexamethasone Drug Delivery
System in the Treatment of Macular Edema Due to Branch and Central
Retinal Vein Occlusion” Reunión Allergan, Madrid 16 octubre 2009
10.2.244. Jordi Monés at the ERAB Allergan Advisory Board Meeting,
Irvine, California USA, Oct 22
10.2.245. Jordi Monés: Curso DMAE seca "El nuevo reto".40 Congrés de
la Societat Catalana d’Oftalmologia Barcelona, 19-21 Nov 2009
10.2.246. Jordi Monés: Mesa Redonda Degeneración Macular Asociada a
la Edad: Nuevas perspectivas terapeúticas. 40 Congrés de la Societat
Catalana d’Oftalmologia Barcelona, 19-21 Nov 2009
10.2.247. Jordi Monés: OCT alta resolución y autofluorescencia en DMAE
seca. Curso Ultimas novedades para el tratamiento DMAE húmeda y
DMAE seca. 40 Congrés de la Societat Catalana d’Oftalmologia
Barcelona, 19-21 Nov 2009
10.2.248. Jordi Monés: DMAE Exudativa y atrófica. Nuevos advances.
C. Vitae Jordi Monés 71
Ateneo de Madrid, Conferència Reunión –Colegio de Farmaceúticos.
Madrid 24 nov 2009
10.2.249. Jordi Monés: DMAE: 20 anys de viatge. Curs optics. Escola
òptica de Terrassa, 26 Nov 2009
10.2.250. Jordi Monés Anti-VEGF for Atypical Indications. The 8th
International Symposium on Ocular Pharmacology and Therapeutics.
Dec 3-6 2009, Rome Italy
10.2.251. Jordi Monés 'Anti-VEGF for myopic CNV. The 8th International
Symposium on Ocular Pharmacology and Therapeutics. Dec 3-6 2009,
Rome Italy
10.2.252. Jordi Monés Imaging autofluorescence and high resolution
optical coherent tomography .symposium Heidelberg, The 8th
International Symposium on Ocular Pharmacology and Therapeutics.
Dec 3-6 2009, Rome Italy
10.2.253. Jordi Monés Anti-C5 therapy in DRY AMD (Ophthotech) The 8th
International Symposium on Ocular Pharmacology and Therapeutics.
Dec 3-6 2009, Rome Italy
10.2.254. Jordi Monés, Nuevas perspectivas en el Tratamiento de la
DMAE seca. IV Symposium sobre controversias en Oftalmologia.
Hospital de Bellvitge, Barcelona Feb 2010.
10.2.255. Jordi Monés at the ERAB Allergan Advisory Board Meeting
Paris, France january 14, 2010
C. Vitae Jordi Monés 72
10.2.256. Anti Complement C5 Therapy in DRY AMD: PHASE I CLINICAL
TRIAL 33rd Annual Macula Society meeting in Tucson, Arizona, Feb
24-27, 2010
10.2.257. Terapia Anti Complemento C5 en DMAE SECA: ENSAYO FASE
I. Congreso Sociedad Española de Retina Vitreo, Santiago de
Compostela, march 5-6, 2010
10.2.258. DMAE seca: Nuevos avances. “Curso Formación Continuada
Instituto Barraquer: Diagnóstico y tratamiento de las afecciones de la
Mácula. Barcelona, April 16, 2010.
10.2.259. Jordi Monés Jordi Monés Investigator Meeting for the Phase 2
Anti-PDGF Study (OPH1001) World Ophthalmology Congress, Berlin
June 4th 2010.
10.2.260. Jordi Monés at the Reonet Novartis Advisory. World
Ophthalmology Congress, Berlin June 9th 2010
10.2.261. Avenços en el tractament de la DMAE exudativa i DMAE
atròfica. Conferència al Col.legi de Metges de Lleida. Lleida, June 7,
2010
10.2.262. Nous tractaments en la DMAE. Conferència Col.legi d’Òptics de
Barcelona. Barcelona, June 30, 2010
10.2.263. El tratamiento de las oclusiones venosas con un implante
intravítreo de dexamentasona (OZURDEX) Ponencia Oficial Congreso
de la Sociedad Española de Oftalmología, Madrid September 2010
C. Vitae Jordi Monés 73
10.2.264. Dry AMD: The new challenge. Heidelberg Spectralis
Symposium. Congreso de la Sociedad Española de Oftalmología,
Madrid September 2010
10.2.265. ¿Cuándo dejar de tratar con anti VEGF? Symposium Novartis.
Congreso de la Sociedad Española de Oftalmología, Madrid September
2010
10.2.266. Course and Wet lab on ozurdex application, Uppsala, Sweden
September 30, 2010
10.2.267. ERAB Advisory Board on Retinal Vein Occlusion, Chicago,
October 17, 2010
10.2.268. The Rationale of the Fusion Regimen of intravitreal ranibizumab
for exudative AMD. 10th International AMD and Retina Congress,
Lugano, 29-30 October 2010 Switzerland.
10.2.269. Chairing Session on Management of Neovascular AMD - Current
therapy and future options, 29 October. Speakers Frank Holz
(Germany), Paolo Lanzetta (Italy), José Cunha-Vaz (Portugal) Peter
Kaiser (USA) 10th International AMD and Retina Congress, Lugano,
29-30 October 2010 Switzerland.
10.2.270. Avenços en el Tractament de la DMAE. Escola Universitaria de
Óptica y Optometría de Terrassa, November 26, 2010
10.2.271. 5th EVICR.net Members Meeting- London, 15/16 November
2010
10.2.272. Meeting of the AMD and Retinal Dystrophies Expert Committee
C. Vitae Jordi Monés 74
of the European Vision Clinical Research Netwwork (EVICR.net)
London, 15/16 November 2010
10.2.273. Reunión Comité Asesor para Eylea® (VEGF-Trap eye) Bayer
Schering Pharma Barcelona, November 20, 2011
10.2.274. DMAE atrófica. Perspectivas presentes y futuras de tratamiento.
Dr. Jordi Monés (Barcelona) Santa Lucia 2010. Sociedad Oftalmológica
de la Comunidad Valenciana, Valencia, December 13, 2010
10.2.275. Region Europe Ophthalmics Network (REONET) advisory board
meeting in Paris, France, on 13th January 2011
10.2.276. Meeting of the European writing Committee of the European
guidelines for the treatment of the macular edema secondary to retinal
vein occlusion. Paris, January 13, 2011
10.2.277. ERAB Advisory Board on Retinal Vein Occlusion, Paris January
15, 2011
10.2.278. Lecture "El nou pas en la DMAE exudativa" Col-legi Oficial
d’Optics i Optometristes de Catalunya, Barcelona, january 24, 2011
10.2.279. Lecture "Esport i trauma ocular ". Col-legi Oficial d’Optics i
Optometristes de Catalunya, Barcelona, january 24, 2011
10.2.280. 2011 Eylea Advisory Board Meeting on VEGF Trap, Bayer.
Miami,February 13, 2011
10.2.281. Dispositivos intravitreos de liberación corticoides en edema
C. Vitae Jordi Monés 75
macular diabètico", Symposium Vitreo Retina, Bausch and Lomb,
Museo Reina Sofia, Madrid March 3, 2011
10.2.282. Member of the Local Advisory Board of The 2nd World
Congress on Controversies in Ophthalmology (COPHy), Barcelona,
Spain, March 3-6, 2011
10.2.283. Debate: Is SD-OCT necessary and sufficient to guide clinical
decisions in neovascular AMD or diabetic macular edema? Yes U.
Schmidt-Erfurth, Austria No J Mones Spain The 2nd World Congress
on Controversies in Ophthalmology (COPHy) Barcelona, Spain, March
3-6, 2011
10.2.284. Debate: Is SD-OCT necessary and sufficient to guide clinical
decisions in neovascular AMD or diabetic macular edema? Yes U.
Schmidt-Erfurth, Austria No J Mones Spain The 2nd World Congress
on Controversies in Ophthalmology (COPHy) Barcelona, Spain, March
3-6, 2011
10.2.285. Jordi Monés, Moderator of the Round Table Management of
Retinal Vein Occlusion The 2nd World Congress on Controversies in
Ophthalmology (COPHy) Barcelona, Spain, March 3-6, 2011
10.2.286. Ophthotech Advisory Board ARVO Meeting, Fort Lauderdale
May 2, 2011
10.2.287. ERAB Advisory Board on Retinal Vein Occlusion, ARVO
Meeting, Fort Lauderdale May 3, 2011
10.2.288. Iluvean Allimera Advisory Board Euretina Meeting. London UK
May 25 2011
C. Vitae Jordi Monés 76
10.2.289. 2nd 2011 Eylea Advisory Board Meeting on VEGF Trap, Bayer.
Euretina Meeting. London UK, May 27, 2011
10.2.290. Novartis Advisory Board Euretina Meeting. London UK, May 28,
2011
10.2.291. ERAB Advisory Board on Retinal Vein Occlusion, Euretina
Meeting. London UK, May 29, 2011
10.2.292. Análisis de los resultados del Estudios CATT e IVAN Día de la
Subespecialidad. Congreso de la Sociedad Española de Oftalmología,
Oviedo SPAIN, 21 Sept, 2011
10.2.293. Hyporreflective wedge in geographic atrophy secondary to AMD.
Un under-reported finding. Reunión Expertos y Junta de la Sociedad
Española de Retina Vitreo. Congreso de la Sociedad Española de
Oftalmología, Oviedo, SPAIN 21 Sept, 2011
10.2.294. Nuevos hallazgos mediante OCT spectral domain en DMAE
atrófica. Symposium Bloss, Congreso de la Sociedad Española de
Oftalmología, Oviedo, SPAIN 22 Sept, 2011
10.2.295. Eficacia y seguridad. Resultados del estudio CATT. Congreso de
la Sociedad Española de Oftalmología, Oviedo, SPAIN 22 Sept, 2011
10.2.296. Algoritmos de tratamiento de las oclusiones venosas de retina.
Simposium Allergan. Congreso de la Sociedad Española de
Oftalmología, Oviedo, SPAIN 22 Sept, 2011
10.2.297. Camp Nou Sense Fum. Assemblea de Socis Compromisaris del
C. Vitae Jordi Monés 77
Futbol Club Barcelona, 24 sept, 2011.
10.2.298. Does foveal swelling exist in foveal sparing of geographic
atrophy secondary to AMD?. Spectralis Meeting. Edimburg, UK 1 Oct
2011
10.2.299. The Rationale for the FUSION regimen in exudative AMD.
Spectralis Meeting. Edimburg, UK 1 Oct 2011
10.2.300. The FUSION regimen. Novartis Advisory Board. American
Academy of Ophthalmology. Orlando, 20 Oct, 2011.
10.2.301. Intravitreal safety delivery: Meet the experts 11 international
AMD and Retina Congres, lisbon 4-5 nov 2011
10.2.302. Ocular neovacularization in RVO Meet the experts 11
international AMD and Retina Congres, lisbon 4-5 nov 2011
10.2.303. International Expert Summit. The Angiogenesis Foundation.
Berlin, 14-15 nov 2011
10.2.304. Steering Committee meeting of Crystal and Bravo Trial for RVO.
Prague, 17 nov,2011
10.2.305. Prohibited Treatments during the Chrystal and Brighter Trials.
Investigator Meeting, Prague, 17 nov,2011
10.2.306. Endpoints in Crystal and Brighter Trials. Investigator
Meeting, Prague, 17 nov,2011
C. Vitae Jordi Monés 78
10.2.307. Utilidad de los anti VEGF en oclusión venosa de la retina. III
Jornadas Vitreo Retina Canarias (VCR). Puerto de la Cruz, 26 Nov,
2011.
10.2.308. Targeting Anti Complement anti C5 therapy for geographic
atrophy secondary to age-related macular degeneration. A phase I
study. International Symposium of Pharmacology and Therapeutics.
Vienna, Dec 1-4, 2011
10.2.309. Chair of Dry AMD and Free Paper Session. International
Symposium of Pharmacology and Therapeutics. Vienna, Dec 1-4, 2011
10.2.310. ICG silent polypoidal vasculopathy with favourable response to
thermal laser therapy. Wet AMD Panel. Case Presentation and
Discussion. International Symposium of Pharmacology and
Therapeutics. Vienna, Dec 1-4, 2011
10.2.311. Chair of Wet AMD II and Free Paper Session. International
Symposium of Pharmacology and Therapeutics. Vienna, Dec 1-4, 2011
10.2.312. Targeting platelet Derived (PDGF) and vascular endothelial
(VEGF) growth factors for neovascular AMD. Phase I and Phase II.
International Symposium of Pharmacology and Therapeutics. Vienna,
Dec 1-4, 2011
10.2.313. Fusion Regimen for Ranibizumab; combination of OCT guided
retreatment with fixed retreatment. (PRN+FIXED) for wet AMD.
International Symposium of Pharmacology and Therapeutics. Vienna,
Dec 1-4, 2011
10.2.314. ERAB Advisory Board Meeting on Retinal Vein Occlusion,
C. Vitae Jordi Monés 79
International Symposium of Pharmacology and Therapeutics. Vienna,
Dec 1-4, 2011
10.2.315. Jordi Monés, RVO expert panel meeting. Rome, 29th January
2012
10.2.316. Iluvean Allimera Advisory Board Meeting. WOC, Abu Dhabi,
UAE February 17, 2012
10.2.317. Region Europe Ophthalmics Network (REONET) advisory board
meeting. Valencia, Spain, March 1, 2012
10.2.318. Jordi Monés, Líneas de Investigación en la DMAE atrófica.
Programa de Postgrado Diagnóstico y tratamiento de las afecciones de
la mácula. Institut Univeristari Barraquer. Barcelona. March 16, 2012
10.2.319. Discussion: People with large drusen in both eyes are at
increased risk of progressing to choroidal neovascularization or
geographic atrophy or both following cataract surgery. Yes Y. Durlu,
Turkey No J Mones, Spain . The 3rd World Congress on Controversies
in Ophthalmology (COPHy) Istanbul, Turkey, March 22-25, 2012
10.2.320. Jordi Monés, Iluvien or Ozurdex. The 3rd World Congress
on Controversies in Ophthalmology (COPHy) Istanbul, Turkey, March
22-25, 2012
10.2.321. Jordi Monés, Moderator of the Round Table Management of
Macular Edema from Retinal Vein Occlusions. The 3rd World Congress
on Controversies in Ophthalmology (COPHy) Istanbul, Turkey, March
22-25, 2012
C. Vitae Jordi Monés 80
10.2.322. Jordi Monés, Inflammation and ME. Aria workshop. Enlighten
meeting, Barcelona, Spain, April 14th 2012
10.2.323. Jordi Monés, Clinical signs and characteristics: how to recognize
inflammation in clinical practice. Aria workshop. Enlighten meeting,
Barcelona, Spain, April 14, 2012.
10.2.324. Jordi Monés, moderador, Seguridad sistémica de los fármacos
de uso intravítreo. Actualización de las terapias intravítreas con
fármacos Anti – VEGF Novartis. Barcelona, Spain, April 26, 2012
10.2.325. Jordi Monés, Moderator Poster Session 547. AMD Clinical
Research VII Jordi M. Monés. Centro Medico Teknon, Institut de la
Màcula i de la Retina, Barcelona, Spain. May 10, 2012 ARVO Meeting,
Fort Lauderdale, Florida, USA
10.2.326. 6530/A532 - Hyporeflective Wedge-Shaped Band in Geographic
Atrophy Secondary to Age-Related Macular Degeneration: An Under-
reported Finding Jordi M. Mones, Marc Biarnes, Fabio M. Trindade.
Centro Medico Teknon, Institut de la Màcula i de la Retina, Poster
Session 547. AMD Clinical Research VII Barcelona, May 10, 2012
10.2.327. 6531/A533 - Optical Coherence Tomography Characterization of
Apparent Foveal Swelling in Patients with Foveal Sparing Secondary to
Geographic Atrophy. Fabio M. Trindade, Jordi Mones, Marc Biarnes.
Institut de la Màcula i de la Retina, Barcelona, Spain. Poster Session
547. AMD Clinical Research VII Barcelona, May 10, 2012
10.2.328. 6532/A534 - Reproducibility of Fundus Autofluorescence
Patterns in Geographic Atrophy Secondary to Age-Related Macular
Degeneration. Marc Biarnes, Jordi Mones, Fabio M. Trindade. Institut
de la Màcula i de la Retina, Barcelona, Spain. Poster Session 547.
AMD Clinical Research VII. Barcelona, May 10, 2012
C. Vitae Jordi Monés 81
10.2.329. Jordi Monés, Evaluation of 2-year CATT and 1-year IVAN
results. Novartis Canada Ophthalmology Advisory Board Meeting - Fort
Lauderdale, FL. Canada, May 7, 2012.
10.2.330. Jordi Monés, Intravitreal Expert Group HFMEA Review Meeting
Fort Lauderdale, Florida, USA. May 5, 2012
10.2.331. Jordi Monés, AMD experts group New trial discussion. Bayer
Meeting, Fort Lauderdale, Florida, USA. May 8, 2012
10.2.332. Jordi Monés, Conferència “Barça sense fum: l’èxit d’una
iniciativa pionera”, Jornada “Día mundial sin tabaco”, Centro Médico
Teknon. Barcelona, May 31, 2012
10.2.333. Jordi Monés, Fusion regimen: ranibizumab in treatment naive
patients with exudative age-related macular degeneration and high
visual acuity. XXVIIIth Meeting of the Club Jules Gonin. Reykjavik,
Iceland, June 20- 23, 2012
10.2.334. Campaign Presentation: "Quit Smoking with Barça" with the
participation of John DALLI, Member of the EC in charge of Health and
Consumer Policy; Sandro ROSELL, President of FC Barcelona and
Jordi MONES i CARILLA, Medical Director of FC Barcelona. September
18, 2012.
10.2.335. Speaker training Eylea. Bayer. Dr. Jordi Monés, member of the
Steering Committee. Berlin, September 24, 2012.
10.2.336. Vitreo-retina (Paneles 001 al 013). Dres. Ramón TORRES y
Jordi MONÉS. 88 Congreso de la Sociedad Española de Oftalmología.
Barcelona, September 27, 2012
10.2.337. Simposium: Controversias en retina. Panel de Discusión DMAE:
¿Es necesario el seguimiento mensual en DMAE? Extensión de los
periodos de seguimiento. Dr. Jordi Monés . 88 Congreso de la
Sociedad Española de Oftalmología. Barcelona, September 27, 2012.
C. Vitae Jordi Monés 82
10.2.338. Mesa: Terapia proactiva - cambiando el abordaje actual en el
tratamiento de la DMAE. Tratamiento proactivo: Siguiente paso en el
abordaje de la DMAE. Individualizar el tratamiento proactivo. Dr. Jordi
Monés. 88 Congreso de la Sociedad Española de Oftalmología.
Barcelona, September 28, 2012.
10.2.339. Presentación: Nuevo hallazgo en las capas de la retina de
pacientes con atrofia geográfica secundaria. Dr. Jordi Monés. II
Reunión de Expertos en Retina Heidelberg. Barcelona. September 27,
2012.
10.2.340. Round table discussion: Are EU citizens health literate and
aware of healthy lifestyles? Dr. Jordi Monés. 15th European Health
Forum Gastein. European Comission. Brusel•les. October 3-6, 2012.
10.2.341. Institutional opening speech: IV Jornadas de MuscleTech
Network. Dr. Jordi Monés. Barcelona, October, 2012.
10.2.342. Conferencia: Degeneración macular asociada a la edad (DMAE).
Dr. Jordi Monés. Associació Discapacitat Visual Catalunya. Barcelona.
October, 2012.
10.2.343. Inaugurazione ufficiale LETTURA MAGISTRALE: In the search
for the optimal regimen and new perspectives in the treatment of AMD.
J. Monés. 3° Congresso Nazionale dell`Associazione Italiana Medici
Oculisti. October 26, 2012.
10.2.344. Meet the expert session. Anti-VEGF therapy in other retinal
diseases (excluding AMD, DR and RVO) The management of myopic
CNV. Jordi Monés and Paolo Lanzetta. 12th International AMD and
Retina Congress. Prague. November 2, 2012.
10.2.345. Session: The management of neovascular AMD. Interactive
clinical case 4: Treatment of RAP in the anti-VEGF era. Dr. Jordi
Monés. 12th International AMD and Retina Congress. Prague.
C. Vitae Jordi Monés 83
November 3, 2012.
10.2.346. Conferencia inaugural: Barça sin humo y Quit Smoking with
Barça: por unos corazones con futuro. V Congreso Clínico semFYC en
Cardiovascular. Barcelona, November 22, 2012.
10.2.347. Taula rodona: Retina mèdica. DMAE seca. Dr. Jordi Monés. 43è
Congrés de la Societat Catalana d’Oftalmologia. Barcelona, November
30, 2012.
10.2.348. Conferencia: Líneas de Investigación de la Barcelona Macula
Foundation. Dr. Jordi Monés. A.A.R.P.C. Seu de l’ONCE. Barcelona.
December 1, 2012.
10.2.349. Edema Macular Diabetic. Allergan Advisory Board Meeting.
Barcelona. December 2, 2012.
10.2.350. Actualización en el manejo de la DMAE y el Edema macular. A
cargo del Dr. Jordi Monés. Curso a cargo de la Delegación de Islas
Baleares del Colegio Nacional de Ópticos –Optometristas de España
(CNOO). Mallorca. December 15, 2012.
10.2.351. Ex-smokers are unstoppable. "Quit Smoking with Barça". A
cargo del Dr. J. Monés. Delivering success stories in public health for
EU citizens. EU Health Prize for Journalists 2012. European Comission.
Brussels. January 30, 2013.
10.2.352. La experiencia de la campaña "Quit Smoking with Barça". Dr.
Jordi Monés.: IIIas Jornadas de la SCATT. CaixaForum, Barcelona.
February 08, 2013.
10.2.353. Dry AMD. The Complement System in Dry AMD: a Therapeutic
Target. Dr. Jordi Monés. International Symposium on Ocular
Pharmacology and Therapeutics (10TH ISOPT Clinical). March 08,
2013.
10.2.354. Wet AMD. Combination Therapy Targeting VEGF and PDGF for
C. Vitae Jordi Monés 84
Wet AMD by Jordi Mones. International Symposium on Ocular
Pharmacology and Therapeutics (10TH ISOPT Clinical). Paris. March
09, 2013.
10.2.355. Wet AMD. Case Discussion/Wet AMD Panel. Panel: Paulo
Lanzetta, Italy, Jordi Mones, Spain, Gisele Soubrane, France & Pravin
Dugel, USA. International Symposium on Ocular Pharmacology and
Therapeutics (10TH ISOPT Clinical). Paris. March 09, 2013.
10.2.356. Tobacco Control, Smoking Cessation and Sports Stadia.
Establishing a Club-Led ‘Smokefree Stadia Policy’ for Camp Nou by Dr.
Mones. European Healthy Stadia Conference 2013. Manchester City
FC. March 21st, 2013.
10.2.357. Debate: Management of center-involved DME and 20/50 in
pseudophake? Anti-VEGF by J. Mones. World Congress on
Controversies in Ophthalmology (COPHy). Budapest. April 04-07, 2013.
10.2.358. Debate: Which regimen: PRN vs. Fixed regimen? Treat and
extend by J. Mones. World Congress on Controversies in
Ophthalmology (COPHy). Budapest. April 04-07, 2013.
10.2.359. AVANCES EN DMAE Coordinadores: Jordi Monés (España),
Lihteh Wu (Costa Rica), Virgil Alfaro (EEUU). Caracterización de
hallazgos foveales y velocidad de progresión de la atrofia geográfica.
Jordi Monés. XXI Curso Panamericano. Galicia. April 27, 2013.
10.2.360. Guest speaker. Novartis Canada Regional Consult Panel.
Vancouver, British Columbia. May, 4th, 2013.
10.2.361. Novartis Scientific Experts Forum ‘Sharing experience in wet
AMD: real choices for real patients?. “The optimization of anti-VEGF
dosing regimens” Jordi Monés. 2013 ARVO Annual Meeting. Seattle,
Washington. May 5th – 8th, 2013.
10.2.362. Assessment of linearity of growth in time in geographic atrophy
C. Vitae Jordi Monés 85
secondary to age-related macular degeneration. 6298 Poster Board
Number: D0114. Jordi M. Mones, Marc Biarnes. 2013 ARVO Annual
Meeting. Seattle, Washington. May 5th – 8th, 2013.
10.2.363. Main Session: Dry AMD. Characterization of retinal layers in
foveal sparing secondary to gepgraphic atrophy by Jordi Monés. 13th
EURETINA Congress. Hamburg, Germany. September 26th-29th,
2013.
10.2.364. REONET Advisory Board. NOVARTIS. Amsterdam. October 4th,
2013.
10.2.365. Curso de actualización en investigación sobre enfermedades
raras: distrofias de la retina. Distrofias de la retina: Diagnóstico,
tratamiento y seguimiento de los pacientes. Dr. Jordi Mones. IIS-FJD
Catedra Bidons Egara CIBERER y CIBER BBN. Universidad Miguel
Hernandez. Madrid, España. Octubre 9, 2013.
10.2.366. EVICR.net Expert Committees. AMD and retinal distrophies.
Coordinator: Jose Sahel, MD, PhD. Members: Rufino Silva, Bart Leroy,
Adnan Tufail, Frank Holz, Jordi Monés, Ugo Introini. Co-opted Member:
Carel Hoyng. The EVICR.net Annual Meeting. Paris, France. October
14-15th, 2013.
10.2.367. Institutional opening speeches Jordi Monés, FCB. 5th
MuscleTech Network Workshop. Barcelona, Spain. October 14th-15th,
2013.
10.2.368. ROCHE SYMPOSIUM. Dr. Jordi Monés. 13th International AMD
& Retina Congress. Londres, England. October 24th, 2013.
10.2.369. 13th International AMD and Retina Congress. The Long-Term
Management of AMD: Efficacy, Safety and Economic Considerations.
Keypad case presentations Sobha Sivaprasad, UK; Jean-Francois
Korobelnik, France; Jordi Monés, Spain; Rafael Navarro, Spain. Panel
C. Vitae Jordi Monés 86
Discusion. 25th October 2013. Dublin, Ireland.
10.2.370. ESASO Style Debates and ESASO Master Classes. Sessions
concurrent: Delegates to attend one session from the choice below.
Master Class 2: New imaging techniques: Instrumentation for
visualizing the instruments of vision. Emin Ozmert, Turkey Jordi Monés,
Spain. 13th International AMD and Retina Congress. Dublin, Ireland.
October 25th, 2013.
10.2.371. Avenços en el tractament de la degeneració macular i altres
malalties de la retina. Dr. Jordi Monés. Fundació Josep Palau Francas.
Ripoll, España. Novembre 12, 2013.
10.2.372. Advisory Board Novartis. AAO Annual Meeting. New Orleans.
November 16th- 19th, 2013.
10.2.373. Advisory Board Alcon. AAO Annual Meeting. New Orleans.
November 16th- 19th, 2013.
10.2.374. Simposi Bayer. Dr. Jordi Monés. 44è Congrés de la Societat
Catalana d'Oftalmologia (SCO). Barcelona, Espanya. Novembre 28-30,
2013.
10.2.375. Líneas de investigación en la DMAE atrófica. Dr. Jordi Monés.
Diagnóstico y tratamiento delas afeccionesde la mácula. Programa de
Postgrado. Institut Universitari Barraquer. Barcelona, Espanya. 14 de
febrero de 2014
10.2.376. Subtle details in inclusion criteria may be the key for success of
clinical trials for chronic conditions. Speaker: Dr. Jordi Monés. GLOBAL
HEALTH VISION LECTURE SERIES. Sponsor: National Eye Institute
(NEI). Co-sponsors: Fogarty International Center (FIC) AND NIH Global
Health Interest Group (GHIG). National Institutes of Health (NIH) Main
Campus, Bethesda, MD. February 19, 2014.
10.2.377. SESSION I. Dry AMD. Impact of a Lesion Size-Derived
C. Vitae Jordi Monés 87
Classification of Geographic Atrophy in Progression Rate. Moderator
and speaker: Jordi Monés. 37th Annual Scientific Program, Macula
Society 2014. Key Largo, Florida. February 20, 2014.
10.2.378. Mesa Redonda: Manejo de la terapia intraocular. Criterios de
importancia en el manejo terapéutico de la DMAE atrófica. Jordi Mones.
XVIII Congreso De La Sociedad Española De Retina Y Vítreo. Sevilla,
Spain. March 7-8, 2014.
10.2.379. Poster: Comparación entre luz azul, infrarrojo y multicolor en la
identificación de las drusas reticulares. Dr. Hussein Almuhtaseb, Dr.
Josep Badal MD, Marc Biarnés O.D., M.P.H. Dr. Jordi Monés MD, PhD.
XVIII Congreso De La Sociedad Española De Retina Y Vítreo. Sevilla,
Spain. March 7-8, 2014.
10.2.380. Vision Research Day. Novartis Ophthalmic and Alcon. Zürich,
Switzerland. March 14-15, 2014
10.2.381. Retinnova. 7 años en la nueva era by Dr. Jordi Monés
(Chairman Retinnova). Novartis. Madrid, Spain. March 28-29, 2014.
10.2.382. “II Guardons contra el càncer”'. Associació Espanyola Contra el
Càncer (Aecc). Dr. Jordi Monés, Responsible of the Medical and Sport
Performance Department of Futbol Club Barcelona, recull el Premi en
representació del FCBarcelona. Barcelona, Spain. April 2, 2014.
10.2.383. Advisory Board de Bayer. Barcelona, Spain. April 24, 2014.
10.2.384. Advisory Board de Novartis. Madrid, Spain. May 25, 2014.
10.2.385. IV Curso de Actualización en Retina y Vítreo. DMAE no
exudativa y Curso de casos clínicos. Dr. Jordi Monés. Instituto
Oftalmológico Fernández-Vega de Oviedo, Spain. May 23-24, 2014.
10.2.386. Advisory Board de Roche. London, September 10, 2014.
10.2.387. Advisory Board de Teva. London, September 11, 2014.
C. Vitae Jordi Monés 88
10.2.388. Advisory Board de Eylea. London, September 11, 2014.
10.2.389. Advisory Board de Roche. Lampalizumab. London., September
11, 2014.
10.2.390. 14th Euretina Congress. “Ranibizumab: Expanding Horizons in
RVO Management” & “What does early neovascular AMD look like?”.
Dr. Jordi Monés, Chaiman and speaker. Novartis. London, September
11-14, 2014.
10.2.391. 14th Euretina Congress. “Performance characteristics of
multicolour versus blue light and infrared imaging in the identification of
reticular pseudodrusen” Dr. H. Almuhtaseb, Dr. J. Badal, Dr. M. Biarnés
and Dr. Monés. London, September 11-14, 2014.
10.2.392. 14th Euretina Congress. Session: “Individually dosed
ranibizumab, alone or combined with laser, versus laser alone in branch
retinal vein occlusion patients with visual impairment due to macular
edema- 6 month results of the BRIGHTER study”. Dr. Monés together
with M. Larsen, F. Boscia, H. Gerding, I. Pearce, S. Priglinger, R.
Tadayoni, M. Gekkieva and A. Lotery. London, September 11-14, 2014.
10.2.393. 14th Euretina Congress. Session “Efficacy and safety of
ranibizumab 0.5 mg in patients with visual impairment due to macular
edema secondary to central retinal vein occlusion- design and baseline
characteristics of the CRYSTAL study”. Dr. Monés with P. Hykin, H.
Gerding, F. Boscia, R. Tadayoni,S. Priglinger, I. Pearce, W. Stubbings,
M. Gekkieva and A. Cole. London, September 11-14, 2014.
10.2.394. Vitreoretinal Society (SERV) Symposium on pathological
myopia: “Anti-VEGF therapy for choroidal neovascular membranes”. By
Dr. Monés. London, September 11-14, 2014.
10.2.395. Conference Choroideremia: knowledge and therapy. “The
classification and evolution of choroideremia and the structure of the
C. Vitae Jordi Monés 89
retina in patients with the pathology” by Dr. Monés. Organised by
Spanish Choroideremia Association with the collaboration of the
University of the Basque Country. Vitoria, Spain. September 16-17,
2014
10.2.396. Jornada científico divulgativa. “Investigación en DMAE:
exudativa y atrófica. Ensayos Clínicos y pre-Clínicos.” Ponente: Dr.
Monés. Asociación de miopía magna con retinopatías (AMIRES).
Hospital Clínico de Madrid, Spain. Octubre 13, 2014.
10.2.397. 6th MuscleTech Network Workshop. Institucional Opening
Speech. Dr. Jordi Monés. Centro Tecnológico Leitat, el FCBarcelona y
Aspetar. Fútbol Club Barcelona. Barcelona, Spain. Octubre 13, 2014
10.2.398. AAO Chicago Congress. Section VII: First-time Results of
Clinical Trials, Part I. PM BRIGHTER and CRYSTAL Studies Jordi M
Mones MD. Chicago. October 17, 2014
10.2.399. 14th ESASO Retina Academy. MasterClass 2: Chorioretinal
dystrophies. Dr. Jordi Monés, Rafael Navarro. European School for
Advanced Studies in Ophthalmology (ESASO). Istanbul, Turkey.
November 14, 2014.
10.2.400. 14th ESASO Retina Academy. SESSION 4 Evidence-based
management of retinal ischaemia Dr. Jordi Monés. European School
for Advanced Studies in Ophthalmology (ESASO). Istanbul, Turkey.
November 14, 2014.
10.2.401. 14th ESASO Retina Academy. Retinamour Clinical Case
Discussion (Medical) Chair: Lawrence Yannuzzi, USA. Panel:
Christopher Brand, UK. Dr. Jordi Monés, Spain. European School for
Advanced Studies in Ophthalmology (ESASO). Istanbul, Turkey.
November 14, 2014.
10.2.402. 14th ESASO Retina Academy. SESSION 5 AMD Chairs: Ursula
C. Vitae Jordi Monés 90
Schmidt-Erfurth, Austria Marco Zarbin, USA. AMD clinical trials update
Jordi Monés, Spain. European School for Advanced Studies in
Ophthalmology (ESASO). Istanbul, Turkey. November 15, 2014.
10.2.403. ENCUENTRO: “Patologías de la Retina”. Principales
enfermedades de la retina: epidemiología en España y Cataluña.
Futuro e Investigación en las Enfermedades de la Retina. DMAE:
Definición, tipos, síntomas, factores de riesgo. Dr. Jordi Monés. El
Periódico-Novartis. Barcelona, Spain. Noviembre 18, 2014.
10.2.404. Actualización en la Terapia para Distrofias Corio-retinianas. Dr.
Jordi Monés. Fundación José Pastor Fuertes. Valencia, Spain.
December 19, 2014.
10.2.405. Scientific Global Advisory Board Meeting. Alcon. New York.
March 20-22, 2015.
10.2.406. RETINA I. Non–neovascular Age-related Macular Degeneration.
Debate II: Minimizing worsening of geographic atrophy. Might be
feasible with Lamplaziumb. Dr. Jordi Monés. The 6th World Congress
on Controversies in Ophthalmology (COPHy). Sorrento, Italy. March 31-
April 3, 2015.
10.2.407. RETINA II Neovascular Age-related Macular Degeneration.
Debate I: First Line Therapy. Ranibizumab. Dr. Jordi Monés. The 6th
World Congress on Controversies in Ophthalmology (COPHy).
Sorrento, Italy. March 31-April 3, 2015.
10.2.408. Retinal vein occlusions. Evaluation of ranibizumab for macular
ischemia in retinal vein occlusion: evidence from the BRIGHTER and
CRYSTAL studies. Dr. Jordi Mones. Annual Meeting Abstracts. ARVO
2015. Denver, Colorado. May 07, 2015.
10.2.409. Fovista Meeting. Barcelona. May, 15, 2015.
10.2.410. Investigator Meeting. Steering Committee at the International
C. Vitae Jordi Monés 91
Multicenter Clinical Trials Proxima A and Proxima B on Geographic
Atrophy (Roche). Barcelona. May 21, 2015.
10.2.411. Advisory Board Novartis. Paris, France. May 29, 2015.
10.2.412. OCT Angiography Meeting. Roma, Italy. June 6, 2015.
10.2.413. 1st CAM Study Meeting. Capri Meeting. Italy. June 7, 2015.
10.2.414. Global RVO Advisory Board Lucentis. Zurich, Switzerland. June
18, 2015.
10.2.415. Anti-VEGF differentiation: The next chapter in management of
retinal diseases. Bayer Advisory Board. Nice, France. September 16,
2015.
10.2.416. AMD and More. “Nascent” Geographic Atrophy. Dr. Jordi Monés,
Speaker and Moderator. 13th International SPECTRALIS® Symposium
(ISS). Valencia, Spain. October 16, 2015.
10.2.417. GA phenotypes with cluster analysis. Dr. Jordi Monés. The
Meeting of the European project Exploring the combined role of genetic
and non-genetic factors for developing AMD: A systems level analysis
of disease subgroups, risk factors, and pathways (EYE-RISK) Majorca,
Spain. October 17, 2015.
10.2.418. Effect Of Macular Ischaemia On Visual Acuity Outcomes In
Patients With Branch And Central Retinal Vein Occlusion Undergoing
Individualised Treatment With Ranibizumab 0.5 Mg: Results from the
BRIGHTER And CRYSTAL Studies. Poster. Dr. Jordi Monés. Second
prize. 15th ESASO Retina Academy. Barcelona, Catalonia. October 23,
2015.
10.2.419. Geographic atrophy in AMD. MasterClass Number 4. Camiel
Boon and Dr. Monés. 15th ESASO Retina Academy. Barcelona,
Catalonia. October 23, 2015.
C. Vitae Jordi Monés 92
10.2.420. Anti-VEGF vs PRP in Proliferative Diabetic Retinopathy.
Session 4. Dr. Jordi Monés, member of the Panel Discussion. 15th
ESASO Retina Academy. Barcelona, Catalonia.October 23, 2015.
10.2.421. PROXIMA EAC F2F Meeting. Steering Committee of the Roche
Clinical Trials Proxima A and Proxima B to combat atrophic Age-
Related Macular Degeneration (AMD). Dr. Jordi Monés, Member.
Annual Meeting American Academy of Ophthalmology (AOO). Las
Vegas. November 15, 2015.
10.2.422. Steering Committee on exudative AMD of the Vision Academy..
Annual Meeting American Academy of Ophthalmology (AOO). Las
Vegas. November 14-17, 2015.
10.2.423. DMAE. Nuevas Perspectivas. Dr. Jordi Monés.3as Jornadas de
la SEEBV. Madrid, Spain. November 20, 2015.
10.2.424. REONET Meeting. Zurich. December 3-4, 2015.
10.2.425. Progresos en la investigación de las enfermedades
degenerativas de la retina. Dr. Jordi Monés. Asociación Mácula Retina.
Sevilla, Spain. December 10, 2015.
10.2.426. Cluster analysis for GA phenotypes. Jordi Monés/Marc Biarnés.
Big data analysis and machine based learning. Rotterdam, The
Netherlands. January 22, 2016.
10.2.427. Progression of GA. Complex Genetic Retinal Ophthalmology. J.
Mones. 6th Euretina Winter meeting 2016. Rotterdam, The Netherlands.
January 23, 2016.
10.2.428. Efficacy of ranibizumab treatment in retinal vein occlusion
patients with retinal macular ischemia: 24-month data from BRIGHTER
and CRYSTAL. Dr. Monés. ARVO. Seattle. May 5th, 2016.
10.2.429. Diagnóstico y tratamiento de las patologías maculares. Sesión
C. Vitae Jordi Monés 93
DMAE. Dr. Monés. Curso Mácula 2016. Instituto Universitario Barraquer
y Universidad Autónoma de Barcelona. Barcelona (Catalonia). June,
3th, 2016.
10.2.430. B-Debate: Fighting blindness. Future Challenges and
opportunities for visual restoration. Dr. Monés, Scientific leader and
member of the Scientific Committee. Organized by: BIOCAT and Obra
Social “la Caixa” with Barcelona Macula Foundation: Research for
Vision, CRG and Fundació LEITAT. CaixaForum. Barcelona
(Catalonia). September 6th and 7th, 2016.
10.2.431. Macular Degeneration. Where we are in clinical practice.
Session 1. Molecular pathology and biomarkers in age-related macular
degeneration (AMD). Dr. Monés, Scientific leader and member of the
Scientific Committee. B-Debate: Fighting blindness. Future Challenges
and opportunities for visual restoration. Organized by: BIOCAT and
Obra Social “la Caixa” with Barcelona Macula Foundation: Research for
Vision, CRG and Fundació LEITAT. CaixaForum. Barcelona
(Catalonia). September 6th and 7th, 2016.
10.2.432. Session 4. Photonics and imaging. Chair: Dr. Monés and Samir
Patel. B-Debate: Fighting blindness. Future Challenges and
opportunities for visual restoration. Organized by: BIOCAT and Obra
Social “la Caixa” with Barcelona Macula Foundation: Research for
Vision, CRG and Fundació LEITAT. CaixaForum. Barcelona
(Catalonia). September 6th and 7th, 2016.
10.2.433. POSTER 2. Dark adaptation impairment in patients with
drusenB- Míriam Garcia, Marc Biarnés, Anabel Rodriguez, Jordi Monés.
Debate: Fighting blindness. Future Challenges and opportunities for
visual restoration. Organized by: BIOCAT and Obra Social “la Caixa”
with Barcelona Macula Foundation: Research for Vision, CRG and
Fundació LEITAT. CaixaForum. Barcelona (Catalonia). September 6th
and 7th, 2016.
C. Vitae Jordi Monés 94
10.2.434. POSTER 3. Identification of phenotypes in geographic atrophy
using cluster analysis. Marc Biarnés, Clara Ramon, Jordi Monés. B-
Debate: Fighting blindness. Future Challenges and opportunities for
visual restoration. Organized by: BIOCAT and Obra Social “la Caixa”
with Barcelona Macula Foundation: Research for Vision, CRG and
Fundació LEITAT. CaixaForum. Barcelona (Catalonia). September 6th
and 7th, 2016.
10.2.435. POSTER 4. Images of the microscopic in-vivo human retina
acquired using AOSLO. David Merino, Marc Biarnés, Miriam Garcia,
Jordi Monés, Pablo Loza-Alvarez. B-Debate: Fighting blindness. Future
Challenges and opportunities for visual restoration. Organized by:
BIOCAT and Obra Social “la Caixa” with Barcelona Macula Foundation:
Research for Vision, CRG and Fundació LEITAT. CaixaForum.
Barcelona (Catalonia). September 6th and 7th, 2016.
10.2.436. POSTER 5. Innovative procurement for visually impaired people:
Introducing the PRO4VIP project. Anna Borrell, Ramon Maspons, Jean
Patrick Mathieu, Jordi Monés, Vincenzo Alberto Vella. B-Debate:
Fighting blindness. Future Challenges and opportunities for visual
restoration. Organized by: BIOCAT and Obra Social “la Caixa” with
Barcelona Macula Foundation: Research for Vision, CRG and Fundació
LEITAT. CaixaForum. Barcelona (Catalonia). September 6th and 7th,
2016.
10.2.437. Therapeutic approaches to dry AMD. Main Session 10 - New
Insights into Dry AMD. Dr. Mones. 16th EURETINA Congress -
Copenhagen 2016. September, 11th, 2016.
10.2.438. Novartis Spain Advisory board. 16th EURETINA Congress -
Copenhagen 2016. September, 9th, 2016.
10.2.439. Maculogix Advisory Board. 16th EURETINA Congress -
Copenhagen 2016. September, 10th, 2016.
C. Vitae Jordi Monés 95
10.2.440. Novartis Advisory board. 16th EURETINA Congress -
Copenhagen 2016. September, 11th, 2016.
10.2.441. Eye diagnosis Advisory board. 16th EURETINA Congress -
Copenhagen 2016. September, 11th, 2016.
10.2.442. 8th Meeting of the Muscletech Network Workshop. Inaugural Session. Dr. Jordi Monés. Barcelona, Catalonia. October 3rd-4th, 2016.
10.2.443. FCB Universitas project, Sport Innovation Hub. Presented by Dr. Jordi Monés. October, 11th, 2016. FC Barcelona’s office. New York, USA.
10.2.444. Investigator Update Meeting Presentation of Lampalizumab
(ROCHE). Dr. Jordi Monés. Congress of the American Academy of
Ophthalmology (AAO). Chicago.October, 15th-18th, 2016
10.2.445. Alcon Retina Exchange Film Festival. Congress of the American
Academy of Ophthalmology (AAO). Chicago.October, 15th-18th, 2016.
10.2.446. Biennial Ocular Regeneration Meeting. Boston. October, 15th-
18th, 2016.
10.2.447. Sports Technology Symposium 2016. 2nd Edition. Inauguration.
Dr. Jordi Monés as Board Member of FCBarcelona and Comissioner of
FCB Universitas.Barcelona, Catalonia. November 10th, 2016.
10.2.448. Clinical Session. Developments in research and new treatments
for retinal dystrophies. Dr. Jordi Monés. Secció Retina. Hospital Sant
Joan de Déu (HSJD). Esplugues, Catalonia. November, 6th, 2016.
10.2.449. FCB Universitas project, Sport Innovation Hub. Presented by Dr.
Jordi Monés. November 30, 2016. Bologna.
10.2.450. The prospects for research on dry AMD. Dr. Jordi Monés.
Catalan Society of Ophthalmology (SCO). Barcelona, Catalonia.
December 1st-3rd, 2016.
10.2.451. Fovista combination therapy for neovascular AMD. Retina
C. Vitae Jordi Monés 96
Session. Dr. Jordi Monés. 13th International Symposium on Ocular
Pharmacology & Therapeutics (ISOPT) Clinical. Rome, Italy. December
1st-3rd, 2016.
10.2.452. Emerging therapies for retinal degenerations. Dr. Jordi Monés.
13th International Symposium on Ocular Pharmacology & Therapeutics
(ISOPT) Clinical. Rome, Italy. December 1st-3rd, 2016.
10.2.453. POSTER: Results of intravitreal aflibercept in patients with
neovascular age-related macular degeneration without optimal
response to anti-VEGF-A therapy. The Macbeth study (878-A0057).
Marc Biarnés and Jordi Monés on behalf of the Macbeth Study Group.
Annual Meeting of the Association for Research in Vision and
Ophthalmology (ARVO). Baltimore (USA). May 7-11, 2017
10.2.454. POSTER: The LITE study. (309-B0508) Validation of an adaptive
optics scanning laser ophthalmoscope prototype in patients with
degenerative retinal diseases. Lucia Lee Ferraro, MD; David Merino,
PhD; Marc Biarnés, MPH, PhD; Miriam Garcia, OD, MSc; Anna Borrell,
BSc; Pablo Loza, PhD; Jordi Monés,MD, PhD. Annual Meeting of the
Association for Research in Vision and Ophthalmology (ARVO).
Baltimore (USA). May 7-11, 2017
10.2.455. Predictive testing for age-related macular degeneration: are we
there yet? Dr. Jordi Monés. Special Interest Group (SIG). Annual
Meeting of the Association for Research in Vision and Ophthalmology
(ARVO). Baltimore (USA). May 7-11, 2017
10.2.456. DMAE atrófica. Etiopatogenia, Predecir y cuantificar el
crecimiento de la atrofia geográfica. Clasificación de la
autofluorescencia en la atrofia geográfica, para dummies y sus
implicaciones. ¿Hemos entendido la enfermedad? ¿Todas las atrofias
son iguales? Fenotipos y tasas de progresión. Análisis de clúster.
“Nascent GA” y Hyper-reflextive dots. Nuevas hipótesis en los
C. Vitae Jordi Monés 97
mecanismos fisiopatológicos de la atrofia. Dr. Jordi Monés. V Curso de
Actualización en Retina y Vítreo. Instituto Oftalmológico Fernández-
Vega. Oviedo, Spain. 19 May, 2017.
10.2.457. Baja visión 360º: por un buen control de la diabetes, por una
mejor calidad de vida de las personas con baja visión. Dr. Jordi Monés.
Associació de Diabètics de Catalunya, la Associació Discapacitat Visual
Catalunya y Novartis. Barcelona, Catalonia. 26 May, 2017.
10.2.458. Deporte y trauma ocular. Dr. Jordi Monés. Col·legi Oficial
d'Òptics Optometristes de Catalunya (COOOC). Barcelona, Catalonia.
June 29, 2017.
10.2.459. Welcome & Drusen ooze: A novel hypotesis for age-related
geographic atrophy. Dr. Jordi Monés. LIGHT 2017 -International Retinal
Laser Society (LASER). Barcelona, Catalonia. September 7, 2017.
10.2.460. Free Paper Session 3 AMD I. Understanding the natural history
of geographic atrophy secondary to age-related macular degeneration:
Baseline data from proxima A. J. Monés. 17th EURETINA Congress.
Barcelona, Catalonia. September 7, 2017
10.2.461. Eurotimes Satellite Education Programme. Symposia: Managing
Retinal Diseases with Ranibizumab: New Evidence. Moderator: J.
Monés, SPAIN. Sponsored by NOVARTIS. 17th EURETINA Congress.
Barcelona, Catalonia. September 8, 2017
10.2.462. Euretina Update 7. Neovascular AMD – Novel Insights &
Lessons Learned. Combination therapy with a platelet derived growth
factor (PDGF) inhibitor in combination with a vascular endothelial
growth factor (VEGF) inhibitor in exudative AMD. 12.00 J. Monés. 17th
EURETINA Congress. Barcelona, Catalonia. September 9, 2017
10.2.463. Eurotimes Satellite Education Programme. Symposia: Impact of
Geographic Atrophy: Enhancing Our Understanding of the Disease
C. Vitae Jordi Monés 98
Moderator: J. Monés, SPAIN. Sponsored by Roche. 17th EURETINA
Congress. Barcelona, Catalonia. September 9, 2017
10.2.464. Geographic atrophy phenotypes using cluster analysis POS-
41688. M. Biarnés, J. Monés SPAIN. 17th EURETINA Congress.
Barcelona, Catalonia. September 9, 2017
10.2.465. Drusen ooze: A novel hypothesis in geographic atrophy.
ePOSTER- J. Monés, M. Garcia, M. Biarnes, A. Lakkaraju, L. Ferraro
SPAIN. 17th EURETINA Congress. Barcelona, Catalonia. September 9,
2017
10.2.466. A swine model of selective geographic atrophy of outer retinal
layers mimicking atrophic age-related macular degeneration.
ePOSTER- 43339. J. Monés, M. Leiva, T. Pena, G. Martinez, M.
Biarnes, A. Serrano, E. Fernandez SPAIN. 17th EURETINA Congress.
Barcelona, Catalonia. September 9, 2017
10.2.467. Validation of an adaptive optics scanning laser ophthalmoscope
prototype in degenerative disorders: The LITE study. ePOSTER-41696.
M. Biarnés, D. Merino, L. Ferraro, M. Garcia, P. Loza, J. Monés,
SPAIN. 17th EURETINA Congress. Barcelona, Catalonia. September 9,
2017
11. THESIS 11.1. Increased fundus autofluorescence, a biomarker of lipofuscin content, as
a risk factor for the progression of geographic atrophy secondary to age-
related macular degeneration. Autor: Marc Biarnés. Jordi Monés,
Director y Miembro del Tribunal. Barcelona, España. July, 2014.
C. Vitae Jordi Monés 99
11.2. Caracterización fenotípica y terapia génica del ratón Prpf31 A216p.
Autora: Ana María Aramburu Del Boz. Jordi Monés, Miembro del
Tribunal. Sevilla, España. December, 2015.
11.3. Desarrollo de nuevas estrategias terapéuticas para el tratamiento de
enfermedades degenerativas de la retina basadas en vectores no virales
y en técnicas de reprogramación celular. Autora: Ariadna R. Díaz
Tahoces. Jordi Monés, Miembro del Tribunal. Elche, España. December,
2015.
11.4. Implant secundari en pacients afàquics sense suport capsular: lents
fixades a l'iris. Autora: Paula Verdaguer. Directors: José Luis Güell
Villanueva i Jordi Monés Carilla. Tutor: José García Arumí. Barcelona,
Catalonia. 28 de novembre de 2016.
12. COLLABORATION IN JOURNAL EDITION and REVIEWER
12.1. Opthalmology
12.2. Scientific Referee of “ARCHIVOS DE LA SOCIEDAD ESPAÑOLA DE
OFTALMOLOGIA”
12.3. Member Editoral Board Retina Today Journal
12.4. Reviewer of Journal of Ocular Pharmacology and Therapeutics.
13. SCIENTIFIC SOCIETIES MEMBERSHIP
13.1. MACULA SOCIETY (Elected in 2002)
13.2. RETINA SOCIETY (Elected Corresponding Member in 2001)
C. Vitae Jordi Monés 100
13.3. CLUB JULES GONIN (Elected 2014)
13.4. AMERICAN SOCIETY OF RETINA SPECIALISTS (Elected 2009)
13.5. AMERICAN ACADEMY OF OPHTHALMOLOGY
13.6. EURETINA SOCIETY
13.7. EUROPEAN VISION INSTITUTE
13.8. ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY
13.9. EUROPEAN ASSOCIATION FOR VISION AND EYE RESEARCH
13.10. SOCIEDAD ESPAÑOLA DE OFTALMOLOGIA
13.11. SOCIEDAD ESPAÑOLA DE RETINA VITREO
13.12. ACADÈMIA DE CIÈNCIES MÈDIQUES DE CATALUNYA I BALEARS
13.13. SOCIETAT CATALANA D'OFTALMOLOGIA
13.14. MASSACHUSETTS EYE AND EAR INFIRMARY ALUMNI
13.15. INSTITUT BARRAQUER
14. LANGUAGES
14.1. Catalan
14.2. Spanish
14.3. English